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Abstract 
The incidence of oesophageal adenocarcinoma (OA) has increased exponentially 
in the western world over the past few decades. Barrett's oesophagus (BO) is a 
well known precursor of OA with a risk approximately 20 times more than that of 
background population. Regular endoscopic surveillance in patients with BO is 
recommended by most of the national gastroenterological societies. The advantage 
of Barrett's surveillance is to identify early subtle lesions which could then be 
managed early to avoid symptomatic and advanced cancers. The detection of such 
early lesions are challenging as they could be flat and inconspicuous on routine 
endoscopic examination. In the absence of any lesions, four quadrant biopsies 
every 1-2 cm of the whole length of Barrett's oesophagus is advised. This 
technique would map only 5-10% of the surface area of Barrett's segment and 
hence it is associated with significant sampling error. The improvement in 
electronics over the past decade has led to the production of endoscopes with 
better charged coupled devices and image enhancement techniques by altering the 
spectrum of light. 
This thesis examines the role of multi modal imaging in Barrett's oesophagus with 
a focus on detecting dysplasia and early cancer (Ee). Firstly, the role of high 
definition (HD) imaging in routine clinical setting was studied using data from 
patients who have undergone Barrett's· surveillance. The yield of dysplasia by HD 
endoscopy was compared to standard definition (SD) endoscopy in this study. The 
role of narrow band imaging (NBI) with magnification in characterising abnormal 
lesions detected during BO surveillance was evaluated by performing a meta-
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analysis of clinical studies. The role of autofluorescence imaging (AFI) in 
Barrett's oesophagus was examined in detail with a view to understand the 
biological basis of autofluorescence and to improve the specificity of this 
technique as it is associated with significant false positive results in clinical 
studies. A meta-analysis was performed to identify whether AFI has a clinical 
advantage over white light endoscopy in detecting Barrett's dysplasia and the 
inter-observer reliability of this technology was studied using AFI expert and AFI 
non-expert endoscopists. An objective method of measuring the autofluorescence 
intensity was proposed as a ratio of the red to the green colour tone (AF ratio) of 
the area of interest. When the AF ratio of the lesion was divided by the AF ratio of 
the background mucosa, an AF index is obtained. A pilot study was performed to 
identify a cut-off value of AF index to differentiate high grade dysplasia (HGD) 
and EC from non-dysplastic BO. Finally. the biological basis of AF intensity was 
examined using APCmin mouse colonic models. This study looked into the AF 
ratio of the colonic mucosal lesions and correlated it with the amount of collagen 
and elastin in the submucosal tissue. Collagen and elastin are known to be the 
strongest fluorophores of the gastrointestinal tract and the question addressed is 
whether the low AF intensity associated with dysplastic lesions is due to the 
thickening of mucosa or to a reduction of collagen and elastin. 
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CHAPTERl 
INTRODUCTION 
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1.1 Introduction to endoscopic techniques 
1.1.1 History of endoscopy 
The evolution of endoscopic technology over the past century has been closely 
related to the developments in the field of electronics and fibre optics. The credit 
of first gastroscopy goes to Kussmaul in 1868, which was lacking in illumination. 
Even after the invention of the first commercially available incandescent light by 
Thomas Edison in 1878, it took more than a quarter of a century to incorporate 
them into the endoscope. It was Hoffman, who first made an endoscope in 1911, 
which could tackle the tortuosity of the gut using multiple lenses and prisms. A 
semi flexible gastroscope using the same concept was materialised after another 
two decades by the efforts of Wolf and Schindler I. 
A flexible fibre optical imaging device was first built in 1954 but the first use of 
flexible fibre optic endoscope materialised in 1958 by the efforts of Larry Curtis, a 
graduate in physics and Basil Hirschowitz, a trainee in gastroenterology 2. This 
marked a new era in the history of endoscopy to tackle the tortuous and dark 
lumen of gastrointestinal tract, which was not examined using a flexible 
instrument before. The fibre scope was based on optical viewing bundles 
transmitting light focused onto the face of each fibre by repeated internal 
reflections. The image reconstructed at the top of the bundle is transmitted to the 
eye via a focusing lens. The fibres are closely packed, however there is always 
some space between the fibres resulting in a 'packing fraction' that is responsible 
for the fine mesh like effect frequently apparent in the transmitted images. 
Disadvantage of these scopes were the frequent breakage of the fibre optics due to 
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continued flexing of the endoscope, leading to loss of pixels and image quality. 
The technology evolved over the next 3 decades until the invention of charge 
coupled devices (CCD) in 1969. In the late 70's, CCDs were incorporated into the 
endoscopes and this started a new era for endoscopy. The CCDs produced 
electronic images that could be viewed on a television and this improved the 
audience experience and facilitated teaching. Essentially a CCD 'chip' is an array 
of several thousand individual photo cells known as picture elements (pixels) that 
receive photons reflected back from the mucosal surface and producing electrons 
in proportion to light received. The variable levels of charge are sent electronically 
to a video processor, which transposes this analog information into digital data, 
which in tum is processed to produce an image on a television monitor. The pixel 
density ofCCDs have evolved since then to the current standards of high 
resolution endoscopy containing more that 850,000 pixels in the CCD 3. This has 
improved the clarity of images thus facilitating early diagnosis of subtle lesions 
that could be tackled before progressing into an advanced disease. 
Over the past decade, tremendous improvements occurred in the field of 
electronics and endoscopy. This is true in cases of imaging techniques and 
therapeutic capabilities. The introduction of capsule endoscopy and echo 
endoscope was some of the recent innovations that has revolutionised the practice 
of endoscopy. 
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1.1.2 Endoscopy system 
The current standard video endoscopy system comprises of flexible endoscope, 
electronic processor, light source, and a television monitor. The endoscope has a 
control head and a flexible shaft with a manoeuvrable tip. The head contains a 
small and a larger wheel, which assists in the right and left as well as up and down 
movements of the tip respectively. It also has up to four buttons that help in 
freezing the image, printing and so on. The head is connected to a light source via 
an umbilical cord, through which pass other tubes transmitting air, water and 
suction. The vinyl covered shaft contains to and fro wiring and supporting 
electronics to the CCD 'chip' mounted at the distal end. This shaft also houses the 
light guide for providing illumination at the distal tip, control wires for 
manoeuvring the distal tip, a channel for suction that also accepts a variety of 
accessory devices and a channel for insufflations of air and water. The distal end 
unit has the CCD, lens system, opening for the accessory channel, and the light 
guide for providing illumination. 
The umbilicus of the endoscope is connected directly to the light source. This box 
contains a xenon lamp that emits white light, which is passed through a red-green-
blue (RGB) filter in the commonly used Olympus systems. The umbilicus is also 
connected to a video processor that receives the RGB images from the CCD, 
integrates them into a single image that is transmitted to the television monitor. 
Current television monitors offer high definition clarity. 
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1.1.3 New modalities of image enhanced endoscopy 
Advanced techniques are developed to enhance the endoscopic image by 
increasing the resolution of the CCD and using high definition television to view 
the processed images. Currently, endoscopes with integrated zoom lenses and 
microscopes are available and with these technologies, intestinal tissues can be 
imaged at cellular and nuclear levels which provide in-vivo optical histology. 
Image enhancement using dye (chromoendoscopy) or optical methods (Narrow 
Band Imaging (NBI), Fuji Intelligent Chromo Endoscopy (FleE) and I-Scan) 
could allow improved visualisation and characterisation of lesions. 
1.1.4 High resolution and magnification endoscopy 
Conventional video endoscopes were equipped with CCDs of 100 000 to 300 000 
pixels, so that each image is built up from those numbers of individual pixels. This 
is referred to as pixel density, which is important because it relates to the image 
resolution and indicates the ability to discriminate two closely approximated 
points. The higher the pixel density, better the image resolution and this in turn 
will help in identifying subtle lesions. The pixel density of CCDs has improved 
over the years and currently CCDs of 850 000 pixel density are available in the 
market 3. They are called high resolution scopes. Some of the endoscopes are 
equipped with optical zoom facility, by using a movable lens in the tip of the 
scope. The focal distance of these lenses can be controlled by a lever at the head of 
the endoscope. This allows visualisation of mucosa very closely and the micro-
vascular and micro-structural details can be assessed 4-7. Endoscopes with 
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magnification up to 115 times are available commercially. The optical 
magnification is closely related to the high resolution abilities of endoscopes. 
Using the same level of optical magnification, high resolution chips will offer 
much more mucosal details. Image manipulation with electronic zooming is also 
feasible. However the level of magnification is limited and the quality of image 
will be lost after a particular level of magnification, which does not happen with 
optical zoom scopes with high resolution CCDs. 
High resolution endoscopy (HRE) with magnification had been widely studied in 
upper gastrointestinal disorders. Gastric atrophy and H.Pylori gastritis could be 
reliably identified by magnified endoscopic assessment of gastric antrum and 
corpus 8,9. The normal gastric mucosa was seen as honeycomb like sub-epithelial 
capillary network pattern (SECN) with collecting venules (CV). The SECN and 
CV were lost and enlarged white pits were seen in Il.Pylori gastritis. Gastric 
atrophy manifested with loss of normal pit patterns and irregular collecting 
venules. The sensitivity and specificity of these findings were more than 90% 10, 
11. Other investigators have also reported good sensitivity and specificity for 
magnification endoscopy to identify Il.Pylori gastritis 9. Magnification endoscopy 
(ME) is also useful in identifying intestinal villi, which will be useful in patients 
with suspected celiac disease. This could be used to assess the degree of villous 
atrophy and was found to be well correlated with histology 12, 13. 
Patients with reflux symptoms and no macroscopic evidence of oesophagitis are 
labelled as non-erosive reflux disease (NERD). Role of magnifying endoscopy 
was studied in this context to identify subtle changes at the gastro-oesophageal 
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junction. No particular feature was sensitive enough to identify NERD, but 
changes like triangular indentations, apical mucosal breaks, and pinpoint blood 
vessels at the squamo-columnar junction were identified more frequently in the 
patients with reflux disease 14,15. 
In Barrett's oesophagus (BO), role of magnification endoscopy had been studied 
mostly in conjunction with chromoendoscopy. Kara et al found that HRE alone 
could detect most of the dysplastic lesions; the yield of which was improved by 
indigocannine dye and narrow band imaging 16. ME has also been proposed to 
improve yield of specialised intestinal metaplasia in BO. Indigocannine and 
methylene blue were used with ME to identify intestinal metaplasia using ridged 
or villous pit patterns. This has shown significant correlation with histology in 
these studies 17,18. Improved yield of specialised intestinal metaplasia and 
dysplasia was found with acetic acid chromoscopy and magnification as well 19,20. 
HRE was compared with acetic acid chromoscopy, indigocarmine chromoscopy 
and NBI in an inter-observer study of Barrett's oesophagus by Curvers et.al 21 • 
Interestingly, the addition of chromoscopy or NBI did not improve the inter-
observer agreement or yield of dysplasia. The yield for identifying early neoplasia 
with white light images was 86% for all observers, 90% for experts, and 84% for 
non-experts. 
27 
Author 
Rogart 
et af. 22 
Zanoni 
et af. 23 
Pohl 
et af. 24 
Table 1: Diagnostic accuracy of magnification endoscopy to differentiate 
adenomatous from non-adenomatous colonic polyps. 
Year Type of study Patients Lesions Sensitivity Specificity Accuracy 
% % % 
2008 Prospective 131 265 69 86 77 
2007 Prospective 161 213 91 67 84 
2008 Prospective 63 150 84 64 76 
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Magnification endoscopy was used to differentiate adenomatous from non-
adenomatous colonic polyps using pit patterns. Kudo classification of various pit 
patterns in colonic polyps are useful in differentiating non-adenomatous polyps 
(Hyperplastic polyp, inflammatory polyp etc.) from adenomatous polyps and 
colon cancer 25. These include 6 patterns. Patterns I and II were considered non-
neoplastic polyps, IllS, IIIL and IV were considered to depict adenomatous 
polyps. Pattern V, which describes irregular pit patterns, were noted to represent 
cancer. Magnification endoscopy alone was found to have a modest accuracy to 
differentiate these. Diagnostic accuracy of studies which used magnification 
endoscopy is summarised in table 1. However when magnification endoscopy is 
combined with chromoendoscopy, the diagnostic accuracy was significantly 
better. Most reported studies had accuracy more than 90% 26,27. 
1.1.5 Chromoendoscopy 
The use of special stains in combination with magnification endoscopy enhances 
the mucosal details seen at endoscopy with characteristic mucosal appearances 
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in targeting biopsies from suspicious areas and thus improve the yield of dysplasia 
in precancerous conditions like Barrett's oesophagus. Vital stains like Lugol's 
solution and methylene blue are absorbed into the cells and thus highlight the 
surface pit patterns. Contrast stains like indigo carmine are not absorbed into the 
cells but accumulate in pits between cells highlighting mucosal details. Reactive 
stains like Congo red and phenol red react to changing conditions of acid secretion 
and carry a potential with regard to the early detection of gastric cancer. It is 
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important that a special spraying catheter is used permitting optimal dispersion of 
the dye onto the mucosal surface. Even though chromoendoscopy is cheap and 
effective it is underused in the western world compared to the Far East. Also, there 
have been concerns raised as photosensitisation of methylene blue with white light 
can induce formation of reactive oxygen species, causing single strand breaks and 
generation of oxidative alterations within the DNA 30,31. However, this is not the 
case with contrast stains, which are used preferentially, and yields comparative 
results. 
1.1.5.1 Methylene blue chromoendoscopy 
Methylene blue (MB) is an absorptive dye which is probably the most widely 
studied in Barrett's oesophagus. It is taken up by actively absorbing intestinal 
epithelial cells and dysplastic mucosa, but not by normal oesophageal and gastric 
mucosa. During MB chromoendoscopy, specialised intestinal metaplasia (SIM) 
typically stains blue, where as a lighter intensity and increased heterogeneity in the 
staining pattern predict high grade dysplasia (HGD) and/or adenocarcinoma. 
One of the earlier studies by Canto et al investigated the MB staining patterns and 
the yield of SIM and dysplasia in Barrett's. The accuracy of SIM detection was 
90% and they found that light to absent staining and moderate to marked 
heterogeneity were significantly associated with high grade dysplasia or cancer 32. 
Further to this various studies compared the yield ofMB directed target biopsies 
to random biopsies in detection of dysplasia and SIM. Some of the studies 
demonstrated significantly higher yield of SIM using MB chromoendoscopy with 
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sensitivities ranging from 80 to 98% 33,34, while others showed much lower 
sensitivities 35-37. Difference in concentration ofMB, the volume used and the time 
of contact could all be the reasons for this variability in results. The results for 
detecting dysplasia are even more inconsistent. A recent meta-analysis included 9 
studies comparing MB directed biopsies to random biopsies. They found that there 
was no significant incremental yield of SIM and dysplasia with MB 
chromoendoscopy 38. The yield ofSIM with MB was 75% versus 70% for 
random biopsies, and that for dysplasia was 43% and 32% respectively for MB 
targeted biopsies and random biopsies. Sub analysis showed a modest 7% 
incremental yield for detecting HGD and cancer 38. Even among experts there is a 
controversy regarding the ideal ways to target the biopsies. The staining patterns 
for SIM and dysplasia are also controversial, which had made this technique less 
frequently used in the present era. The advent of electronic chromoendoscopy 
techniques which could also provide details on the vascular patterns has 
superseded chromoendoscopy to some extent. 
Colonic MB chromoendoscopy had shown to improve dysplasia detection in 
inflammatory bowel disease 39. There is a paucity of data on MB chromo 
colonoscopy, probably due to the concerns raised about the potential DNA 
damage and the larger volume ofMB necessary compared to upper 
gastrointestinal examination 40. 
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1.1.5.2 Chromoendoscopy with other dyes 
Lugol's iodine is a compound iodine solution which is absorbed by the glycogen 
containing squamous epithelium and stains it dark brown. This is particularly 
useful in identifying oesophageal squamous dysplasia which will appear lighter in 
colour compared to the nonnal squamous epithelium 41-43. It is also possible to 
differentiate the columnar lining and gastric mucosa effectively. In a screening 
study for high risk patients, Lugol's iodine increased the sensitivity of 
oesophageal squamous dysplasia detection significantly 44. In BO, the specialised 
intestinal metaplasia does not stain after Lugol's iodine application. This can be 
used to demarcate the columnar lined oesophagus from the nonnal squamous 
mucosa 45. 
Crystal violet is another absorptive stain which was used in colonoscopic 
assessment of polyps 46,47, as it is taken up by crypts of Liberkuhn 48. Its role in 
Barrett's oesophagus is not clearly understood as there is a paucity of literature. 
Indigocannine (lC) is much more widely used in clinical practice now. This dye is 
not absorbed by the epithelial cells, but augments the mucosal details thus 
enabling to identify mucosal irregularities. The use ofIC in Barrett's oesophagus 
and colonic lesion detection had been widely studied. Shanna et at found that 
magnification endoscopy with indigocannine spray is useful in identifying 
intestinal metaplasia and dysplasia in BO. All patients with HGD had 
irregular/distorted pit patterns on inspection. Ridged/villous pattern were 
suggestive of intestinal metaplasia. However LGD patients also had ridged pattern 
and could not be differentiated from intestinal metaplasia alone 49. However 
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compared to high resolution endoscopy, IC chromoendoscopy (ICC) could detect 
only a limited number of additional dysplastic lesions and did not alter the 
sensitivity of detecting dysplasia 16. Similar results were obtained by Curvers et ai, 
who did not find any improvement in inter-observer variability and yield of 
dysplasia when magnification ICC is compared with magnified high resolution 
images 21. The high resolution endoscopy with the high definition systems and 
magnification are able to provide much more mucosal details compared to the 
previous generation of endoscopes, which could explain these results. 
ICC is much more widely used in colonic lesions for differentiating polyps and 
detecting dysplasia. The adenoma detection rates of ICC were superior to standard 
white light endoscopy in various comparative studies. This was particularly 
sensitive in detecting small and flat adenomas 50-52. Contrary to these findings, one 
of the studies did not find any difference in detecting adenomas using HRE and 
chromoscopy compared to standard endoscopy. However the total number of flat 
lesions detected was better with chromoscopy as with hyperplasic polyps 53. 
ICC seems to be beneficial in characterisation of polyps and differentiating 
adenomatous from non-adenomatous polyps using Kudo pit patterns. The 
sensitivities of ICC vary from 82% to 100% and specificities vary between 82% 
and 95%. The Japanese endoscopists are more experienced than the western 
endoscopists in differentiating the polyp pit patterns and this could explain the 
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33 
Various studies have evaluated the role of ICC in detecting dysplasia during 
ulcerative colitis surveillance. Pan colonic dye spray and targeted biopsies are 
found to have better yield in detecting dysplasia. Rutter et al compared the yield of 
dysplasia in random biopsies and targeted biopsies after ICC. Out of the 2904 non-
targeted biopsies, none of them showed dysplasia in 100 patients. The same 
patients required only 157 targeted biopsies after ICC, and detected 9 dysplastic 
lesions 57. Similarly, magnification ICC was found to improve the yield of 
dysplasia and also helped in characterising detected lesions 58. 
The chromoendoscopy had been in use for more than two decades but has its own 
limitations. The spraying of dye can increase the procedure time and is sometimes 
messy. Also there is a lack of standardisation of the technique, producing variable 
results in the clinical trials. Lack of evidence form well controlled studies to assess 
the clinical utility, cost effectiveness and patient acceptability are some of the 
reasons for its under use, especially so in the western world. 
1.1.6 Fuji Intelligent Chromo Endoscopy (FICE) and I-Scan 
These techniques are based on a new computed spectral estimation technology. 
FICE (Fujinon endoscopy®) and I-Scan (Pentax Medical®) transforms an 
ordinary endoscopic image taken from the video processor and arithmetically 
processes the reflected photons to reconstitute virtual images by increasing the 
relative intensity of narrowed blue light to a maximum and by decreasing 
narrowed red and green light to a minimum. This leads to better delineation of 
microvasculature and mucosal pit patterns due to the differential absorption of 
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light by haemoglobin in the mucosa. FICE has been compared with standard 
endoscopy and indigocarmine chromoendoscopy in colonic polyps to differentiate 
neoplastic polyps from non-adenomatous polyps. The diagnostic accuracy of FICE 
with and without magnification was 83% and 90%. This was significantly better 
than standard endoscopy with and without magnification and was comparable to 
chromoendoscopy 24. A randomised study looked at the adenoma detection rates 
ofFICE without magnification and chromoendoscopy. The detection rates were 
similar; however these results are valuable in that, chromoendoscopy could be 
replaced by FICE which is a dye less technique 59. There is a paucity of data on 
the use of FlCE in upper gastrointestinal tract 60. A recent study has found that 
Barrett's oesophagus can be easily diagnosed with FlCE compared to standard 
endoscopy, with a clear demarcation between the Barrett's segment and gastric 
mucosa 61. More studies are necessary in Barrett's oesophagus comparing to other 
modalities to assess the utility of this new technique. 
I-Scan is the latest addition to the field of electronic chromoendoscopy based on a 
similar mechanism as in FICE. It was found to improve detection of small colonic 
polyps in the left colon compared to high definition colonoscopy. However there 
was no difference in neoplasia pick up rates among I-scan, high definition 
colonoscopy and chromoendoscopy 62. I-scan was found to improve the yield of 
minimal change reflux oesophagi tis compared to white light endoscopy in a 
randomised trial. This study also showed improvement in the inter-observer 
reliability of Los Angeles classification of reflux oesophagi tis 63. 
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1.1.7 Confocal laser endomicroscopy 
The concept of 'optical biopsy' has been achieved in its true sense by the confocal 
laser endomicroscopy. Two systems are commercially available, which includes 
an endoscope with integrated confocal microscope at the tip (Pentax Medical®), 
and a probe based confocal microscope which can be passed through the working 
channel of an ordinary endoscope (Mauna Kea). To create confocal images, blue 
laser light is focused on the desired tissue via the distal end of confocal endoscope. 
Applied fluorescent materials (usually intravenously) are excited by laser lights, 
which is detected by the confocal optical unit in an exactly defined horizontal 
level. Extreme magnification (up to 1000 times) is obtained with this technology 
acquiring images at the cellular/nuclear level mimicking histopathology sections, 
thereby allowing targeted biopsy and reducing the number of random biopsies. 
One of the earliest reports on confocal laser endomicroscopy (CLE) was published 
in 2005, detecting H.Pylori colonisation of stomach in a 70 years old gentleman 64. 
CLE was used in Barrett's oesophagus to study the mucosal morphology and 
predict dysplasia. The sensitivity in predicting intestinal metaplasia and dysplasia 
compared to targeted histology was 98% and 93% with a specificity of 94% and 
98% 65. CLE with optical biopsies or targeted biopsies have shown to improve the 
yield of endoscopically inapparent BO dysplasia in a randomised trial, compared 
to non-targeted biopsies 66. In colon, CLE was found to be highly accurate in 
predicting intra-epithelial neoplasia and differentiating dysplasia associated mass 
lesions and adenomas in ulcerative colitis 67,68. 
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The endocytoscopy is a relatively new addition to the endoscopic magnification 
technology and these are ultra-magnification (450-1125 times) catheter based 
endoscopes that can be passed through the working channel of a standard 
endoscope. In combination with chromo agents, they can provide in vivo 
histological images. Unlike confocal endoscopy, endocytoscopes produce colour 
images but does not scan deeper cellular levels. 
1.1.8 Infra red endoscopy 
This recently developed technology uses near-infrared light, which has limited 
scattering characteristics and low absorption by water and haemoglobin that in 
tum allows deeper penetration into the tissue compared to white light. This 
endoscopy system uses a high performance CCD which is sensitive to infrared and 
white light along with two ranges of infrared light emitted by the light source. 
Intravenously administered indocyanine green dye enables to clearly visualise 
mucosal and submucosal vessels with the infrared light and is found to be useful 
in identifying the depth of gastric cancers. Indocyanine is excited by rays at a 
wavelength of 768 nm to emit fluorescence at a wavelength of 807 nm in the 
infrared (lR) range. Thirty patients with gastric tumours were examined using 
infra red endoscopy. Fluorescence was positive in 8 of 10 gastric cancers with sub 
mucosal invasion and 1 of 20 adenomas or intra-mucosal gastric cancers. IR 
endoscopy could be a useful tool to estimate the depth of invasion of gastric 
lesions 69,70. Further studies are necessary to assess its utility in other parts of 
gastro intestinal tract. 
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1.1.9 Narrow band imaging 
Narrow band imaging (NBI) is a relatively new technology of image enhanced 
endoscopy. It offers advantages of chromoscopy without the use of dye spray. 
This was first described in 2004 by a Gono et al 71 and is patented by Olympus 
corporation, Tokyo, Japan. Standard white light endoscopy uses full visible 
wavelength range of 400 to 700 nm, to produce a red-green-blue image. White 
light from a xenon lamp is passed through a red-green-blue filter (RGB filter) and 
the mucosa is sequentially illuminated with these three colours. The red, green, 
and blue reflected light is detected by a monochromatic charged coupled device 
(CCD) integrated at the tip of the endoscope, and the three images are merged into 
a single colour image by the video processor. In endoscopic systems with NBI, an 
additional filter is activated by pressing a button on the hand control of the 
endoscope. This filter narrows the band widths of the emitted blue (440-460 nm) 
and green light (540-560 nm) and the relative contribution of blue light has been 
increased. The penetration of light into the tissue depends on the wavelength; the 
longer the wavelength, the deeper the penetration. Blue light penetrates only the 
superficial layers; whereas the red light penetrates deeply. By narrowing the 
bandwidths of blue and green light, the superficial mucosal details are better 
visualised. Also, the blue light is absorbed by haemoglobin, enabling visualisation 
of superficial vasculature. The RGB based system and NBI are used mainly in 
Japan and United Kingdom, whereas in other parts of world, a white light 
illumination system with a colour CCD is used. 
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NBI is often called as 'electronic chromoendoscopy' and offers a few advantages 
over traditional chromoendoscopy. NBI is user friendly and does not need any 
additional dyes to be used. It allows uniform visualisation of the endoscopic field, 
whereas the use of dye might not distribute equally over the mucosa. In addition to 
these practical advantages, NBI also allows visualisation of micro vasculature with 
high contrast, which is not possible with chromoscopy. Examining the mucosal 
pit patterns and vascularity using NBI could help in identifying subtle 
abnormalities harbouring dysplasia. This had been widely studied in upper and 
lower gastrointestinal tract. The details oflesion characterisation in colon are 
outlined below (Table 2). 
Table 2: Lesion characterisation in colon using narrow band imaging 
Author Year No of patients No of lesions Sensitivity % Specificity % 
Machida 2004 34 43 91 100 
et al. 72 
Su 2006 78 110 96 88 
et al. 73 
Chiu 2006 133 180 95 72 
et al. 55 
East 2007 20 33 86 80 
etal. 26 
Hirata 2007 99 148 99 94 
et al. 74 
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NBI could be useful in detecting Barrett's dysplasia compared to standard 
resolution white light endoscopy (WLE). In a prospective tandem endoscopy study 
of 65 patients, higher grades of dysplasia were detected by NBI compared to 
WLE. NBI directed target biopsies yielded more dysplasia than WLE directed 
biopsies and the number of biopsies taken by WLE were significantly more than 
that ofNBI 75. An earlier study by Kara et at compared the dysplasia detection 
rates ofHRE, indigocarmine chromoscopy and NBI with magnification. Targeted 
biopsies with HRE alone had a sensitivity of79% in detecting HGD. The addition 
of chromoscopy and NBI did not improve the yield significantly. The first study 
described above, used standard resolution endoscopy, while the latter study used 
liRE. This could explain the variability in the results. More studies are necessary 
to comment on the ability ofNBI in detecting dysplastic lesions 16. 
Narrowband imaging with magnification however could help in assessing the 
micro-structural and vascular patterns of any suspicious areas detected in the 
Barrett's segment (Figure 1-2). Irregular vascular patterns and irregular micro-
structural patterns indicate possibility of dysplasia, while inflammation and 
scarring could be excluded. There are various studies which identified different 
mucosal pit patterns and vascular patterns in dysplastic and non-dysplastic 
Barrett's. Singh et at described four different mucosal pit patterns and two 
vascular patterns (regular or irregular) on NBI with magnification. Type A was 
round pits with regular micro-vasculature. Type B was villous/ridged patterns with 
regular micro-vasculature. Type C patterns showed absent pit patterns with regular 
vascular patterns and type D was irregular pits with irregular micro-vasculature 76. 
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Figure 1: Narrow band imaging with magnification showing regular pit 
patterns and regular micro-vascular patterns in non-dysplastic Barrett's 
Figure 2: Narrow band imaging with magnification showing distorted pits 
and irregular vascular patterns in dysplastic Barrett's 
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Type A pattern was associated with columnar epithelium and the positive and 
negative predictive values were 100% and 89% respectively. Similarly patterns B 
and C were thought to represent intestinal metaplasia and the positive and negative 
predictive values were 90% and 96%. Type D pattern represents HGD or early 
cancer with positive and negative predictive values of 79% and 100%. Reports 
from other studies were variable and some of the investigators used different 
classification systems of the mucosal pit patterns. 
NBI is widely available for clinical use and magnification endoscopes are 
commercially available. In this setting it is important to clarify whether NBI with 
magnification is truly worthwhile on routine surveillance of Barrett's patients. The 
role ofNBI in detecting dysplastic lesions remains controversial, but most of the 
studies used NBI to characterise the detected lesions. IfNBI offers good accuracy 
in characterising lesions, this would help in reducing the number of random of 
biopsies and help in targeting lesions. This also has implications in endotherapy 
where NBI could be used to delineate the lesions based on the pit patterns and 
vascular patterns. 
1.1.10 Autofluorescence endoscopy 
The endoscopic techniques are evolving constantly and we are moving beyond 
white light endoscopy to the newer modalities using the light tissue interaction. 
The phenomenon of autofluorescence occurs when a light of shorter wavelength 
interacts with a tissue containing endogenous fluorophores, which in tum emits 
light of longer wavelength. A number of biological substances in the 
gastrointestinal tract such as collagen, elastin, nicotinamide, and flavins can act as 
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endogenous fluorophores 77. Earlier autofluorescence imaging systems used fibre 
optic endoscopes which failed to produce sufficient image quality for clinical 
utility. However the emergence of high resolution video endoscopy with a second 
CCD for autofluorescence imaging has made it possible to obtain pseudo colour 
images with significant improvement in quality. AFI offers an easy way to 
distinguish between normal and tumorous tissue by combining an auto 
fluorescence image on irradiating with a blue light of wavelength of 390-470 nm. 
The image of green reflected light depicts the absorbed light by haemoglobin, so 
that normal tissue appears pale green and tumour tissue appears magenta. 
There are various studies which examined the role of AFI in Barrett's oesophagus. 
One of the earliest studies used a fibre based laser induced fluorescence system, 
which could be passed through the accessory channel of the endoscopes. 
Panjehpour et al studied this system in 36 patients with BO. The probe was kept in 
close contact with the site of interest and using a foot pedal the measurement was 
taken. Analysis was done using a mathematical model. They found that 96% of 
non-dysplastic Barrett's was classified as benign and 90% HGD as pre-malignant 
78. 5-aminolevulinic acid-induced protoporphyrin IX fluorescence was found to 
identify areas ofHGD with a modest sensitivity of70% in a later study 79. In vitro 
studies on surgical specimens showed that the highest fluorescence ratio was 
obtained in areas of adenocarcinoma, compared to dysplastic Barrett's and non-
dysplastic Barrett's 80. The next generation of light induced autofluorescence 
endoscopes (LIFE) was investigated in the tum of this century. Utility of 
autofluorescence endoscopy to detect the presence and extent of occult malignant 
43 
and premalignant oesophageal and gastric lesions were demonstrated by the 
Amsterdam group in 2001 81. In a randomised crossover trial Kara et al 
investigated the role of AFI in detection of dysplasia in BO compared to WLE. 
The sensitivity ofWLE targeted biopsies was better than that of AFI in this study 
(85% vs. 69%) 82. Thus, AFI did not improve dysplasia detection rates using this 
system. This resulted in introduction of a video autofluorescence endoscope which 
was studied in 2005 again by the Amsterdam group. This was a prototype system 
from Olympus Corporation, Japan, which is a high resolution video endoscope 
that has separate CCDs for WLE and AFI. 22 patients with HGD were examined 
with AFI and WLE. AFI detected additional lesions in 3 patients compared to 
WLE. The use of AFI was found to be feasible and promising in detecting 
dysplasia 83. 
These earlier studies prompted to use AFI as a 'red flag' technique to highlight 
suspected areas in Barrett's which could be closely examined with WLE or NBI 
with and without magnification. One of the disadvantages observed was the high 
false positive rates for AFI and it was hypothesised that this could be improved by 
additional NBI use. Twenty patients with suspected HGD were observed with AFI 
and suspected areas were examined closely with NBI. All the 28 lesions in this 
cohort were picked up by AFI; however there was a false positive rate of 40%. 
This was reduced to 10% by the use ofNBI, thus making a combined approach 
more specific 84. A randomised trial comparing AFI and WLE in Barrett's 
surveillance patients was performed where AFI was found to improve dysplasia 
detection rates. However this did not suggest replacing the standard four quadrant 
44 
biopsy protocols as in 11/19 patients dysplasia was detected only on random 
sampling 85. The combined use ofWLE, AFI and NBI is possible with 
commercially available endoscopes with magnification. These different modalities 
could be used by the press of a button and the operator can switch back and forth 
in seconds. The value of this 'trimodal imaging' was investigated by the 
Amsterdam group. AFI was superior to WLE in detecting dysplastic lesions, but 
the false positivity was high as reported before (81 %). This was reduced to 26% 
after inspection with NBI 86. 
The role of AFI in colonic imaging is less well studied. Back to back colonoscopy 
with AFI and WLE examined the adenoma detection rates, which showed 
increased pick of adenomas in the right colon by AFI 87. However a study from 
Japan, which compared chromoendoscopy, NBI and AFI found that chromoscopy 
is superior to other modalities 88. More well designed studies are necessary in 
colon, to assess the utility of this technique. 
It is possible that the AFI intensity changes with progressing dysplasia and also 
there is likely to be a difference with non-dysplastic and dysplastic Barrett's. This 
could not be easily differentiated endoscopically as areas of inflammation, 
scarring and dysplasia will show low intensity signals (magenta/purple) compared 
to the normal green mucosa on AF imaging (figure 3-4). However, a ratio of the 
'red tone to the green tone' or vice versa analysis of images might be helpful to 
differentiate the true positives from the false positives. 
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Figure 3: High definition white light endoscopy showing a Barrett's cancer 
highlighted in purple on autofluorescence imaging 
Figure 4: Barrett's high grade dysplasia seen as a subtle lesion on white light 
endoscopy highlighted in purple colour on autofluorescence imaging 
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1.2 Barrett's oesophagus 
1.2.1 Epidemiology of Barrett's oesophagus and oesophageal 
adenocarcinoma 
Barrett's oesophagus (BO) is named after Norman Barrett who first described this 
condition in 1950. Various investigators have described conditions similar to this 
since 1906. One of the first descriptions was by a pathologist named Tileston, who 
found 'peptic ulcer of the oesophagus' with surrounding mucosa simulating that of 
stomach. The anatomical origin of this abnormal lining was debated for a few 
decades. Norman Barrett himself believed that, this abnormal lining is in fact due 
to stomach tethered to chest with a congenitally short oesophagus 89. A few years 
later, Allison and Johnstone, published their observations that the abnormal 
columnar lining is from the oesophagus. This was strengthened by their 
observations that the hollow organ contained submucosal glands and muscularis 
layer which are characteristic of oesophagus. Furthermore, they identified 
interspersed squamous islands in the columnar lining, strengthening the argument 
90. In 1957, Barrett agreed with these findings and his name was given to the 
condition where lower oesophagus was lined by columnar epithelium. In 1976, 
Paull et al published details of the various types of the columnar epithelium which 
was identified at the lower oesophagus. These included a gastric fundic type, a 
junctional type and a distinctive intestinal metaplasia, which was called 
specialised intestinal metaplasia 91. The complete specialised intestinal metaplasia 
with goblet cells are since then considered to be the hallmark of Barrett's 
oesophagus. 
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The endoscopic diagnosis remained challenging as the nonnal gastro-oesophageal 
junction (GOJ) was difficult to define in the presence of columnar epithelium. 
Many investigators argued that the distal oesophagus would nonnally contain 
some columnar epithelium. After years of contemplation, the Barrett's subgroup 
of the international working group for classification of oesophagitis (IWGCO) 
developed the Prague criteria to facilitate an internationally acceptable 
nomenclature for endoscopic description of Barrett's oesophagus in 2006 92. 
BO is characterised by replacement of the distal squamous oesophageal epithelium 
by columnar mucosa containing specialised intestinal metaplasia (SIM). The 
specialised intestinal metaplasia is considered to predispose to adenocarcinoma, 
and it could be argued that presence of SIM anywhere in the oesophagus could be 
called Barrett's and not necessarily the metaplasia at the lower oesophagus. 
The average age of diagnosis of Barrett's is 55-65 years with a male 
preponderance at 2: I ratio to females. Although Barrett's oesophagus can affect 
children, this is seldom seen below the age of 5 years, which strengthens the 
argument that Barrett's is an acquired condition. The condition is less often 
reported in the African Caribbean and Asian population compared to white 
Caucasians 93,94, Thus white males in their middle age are the most predisposed 
patients, constituting 80% all cases. The role of smoking, obesity and alcohol in 
the pathogenesis of Barrett's is controversial. Some studies have reported 
progression from non-dysplastic BO to adenocarcinoma in patients with 
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The prevalence of Barrett's in the general population is variable depending on the 
population studied and the definition used. A Swedish population based study 
identified the prevalence as 1.6% of the general population 98. Interestingly, 
around 45% patients with BO lacked significant reflux symptoms in this study, 
which suggests that screening programmes for detecting Barrett's in the 
population with reflux disease would be inadequate. There are reports of familial 
aggregation of Barrett's oesophagus and oesophageal adenocarcinoma. The 
presence of family history with first or second degree relatives having Barrett's 
oesophagus or oesophageal adenocarcinoma was significantly higher in cases than 
controls (24% Vs 5%) 99. Germline mutations in MSRl, ASCCI and CTHRCI 
have been associated with BO and OA in a study conducted in 21 concordant 
affected sibling pairs 100. However, larger cohort studies are necessary to validate 
these findings. 
1.2.2 Aetiology and pathogenesis of Barrett's oesophagus 
Barrett's oesophagus is a well recognised complication of long standing reflux 
disease. Patients who develop BO tend to have a combination of clinical features 
which incJude presence of hiatus hernia and reduced lower oesophageal sphincter 
pressure 101. These predispose to Gastro oesophageal reflux (GORD). Delayed 
oesophageal acid cJearance time and duodeno-gastric reflux facilitating bile in the 
oesophageal lumen are also thought to be predisposing to development ofBO 102. 
There are various oesophageal defence mechanisms in place. The anti-reflux 
barrier includes the high pressure zone at the gastro-oesophageal junction (GOl) 
maintained by the tonic contraction of the lower oesophageal sphincter (LOS). 
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The external compression by the crus of the right diaphragm and the intra-
abdominal location of the LOS also helps to maintain the high pressure at the 
lower oesophagus thus preventing reflux. However the LOS relaxes episodically 
and transiently in healthy persons. Reduction in the LOS pressure can be provoked 
by various dietary factors including chocolate, fatty foods, alcohol and smoking. 
These factors are seen to increase the transient LOS relaxations (TLOSRs). This 
predisposes to reflux of acid, bile, pepsin and pancreatic enzymes causing mucosal 
injury to the oesophagus 103,104. 
The damage to the oesophageal lining is dependent on the duration of acid or other 
noxious substances contact with the mucosa rather than the number of episodes. 
Healthy individuals clear the oesophageal contents in various ways including the 
help of gravity, peristalsis and presence of bicarbonates in the salivary secretions. 
Dysmotility of the oesophageal musculature resulting in weak or ineffective 
peristalsis is an important contributing factor in the pathogenesis of GORD 105. 
80 develops through the process of metaplasia which implies that one kind of 
fully differentiated cell replaces another. Metaplasia occurs as a result of constant 
noxious substance exposure, where the injured mature cells are repaired by 
aberrant differentiation of immature proliferating cells. The metaplastic columnar 
epithelium seems to be a favourable adaptation for long standing reflux as 
columnar epithelium is resistant to reflux compared to squamous epithelium. The 
pattern of acid exposure to the metaplastic epithelium might playa role in the 
progression to dysplasia and cancer. An ex-vivo study showed that pulsed acid 
exposure to the metaplastic epithelium resulted in cellular proliferation as 
so 
compared to constant acid exposure when normal oesophageal, BO and duodenal 
cells were exposed to acid. The authors proposed a model in where diverse 
patterns of acid exposure may be contributing to the heterogeneity and 
unpredictability in progression of neoplasia in Barrett's 106. A strong and probably 
causal relationship between gastro-oesophageal reflux and oesophageal 
adenocarcinoma was reported in a population study and they also suggested that 
the more frequent, more severe, and longer lasting symptoms of reflux are 
associated with higher risk of adenocarcinoma 107. However, this was a case-
control study based on personal interviews with regard to the severity of 
symptoms and is subject to bias. An association is definitely forthcoming but 
causal relationship is difficult to confirm. It was hypothesised that, given the 
propensity of severe reflux disease in patients with long segment BO, the 
metaplasia progressed in extent over the years. However, such extension of length 
ofBO is only rarely seen and it is assumed that BO appears to develop to its full 
length over a short period of time \08. 
Traditionally, 3 different types of columnar epithelia have been described in 
Barrett's oesophagus 91. 
1. Cardia type mucosa- This is also called junctional or cardiac epithelium 
and has a foveolar surface and glands that are lined by mucus secreting 
cells. 
2. Gastric fundic type mucosa- This has a foveolar surface lined by mucus 
secreting cells and a deeper glandular layer containing chief and parietal 
cells. 
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3. Specialised intestinal metaplasia- This has intestinal type crypts lined by 
mucus secreting columnar ceIls and goblet ceIls. 
The specialised intestinal metaplasia (SIM) was the only cellular type which was 
thought to have clear malignant potential. However, in a retrospective study, 
patients with SIM were compared with columnar lined oesophagus without SIM in 
terms of developing adenocarcinoma. No significant difference was seen between 
the groups. The authors concluded that SIM is not essential for cancer risk 109. It 
is quite possible that the lack ofSIM in some of the cases included in the study 
could be due to sampling error. 
1.2.3 Development of neoplasia in Barrett's oesophagus 
The development of dysplasia or cancer in Barrett's oesophagus is a step wise 
process going through a series of changes which are low grade intra-epithelial 
neoplasia or low grade dysplasia (LGD), high grade intra-epithelial neoplasia or 
high grade dysplasia (HGD) and finally cancer 110, III. The metaplastic epithelium 
(SIM) goes through a series of DNA alterations which gives the cells certain 
growth advantages leading to dysplasia. The changes including LGD, HGD and 
intra-mucosal cancer (IMC) are collectively referred to as early neoplasia (EN). 
Dysplasia is recognised by pathologists as a collection of architectural and 
cytological abnormalities including nuclear enlargement, pleomorphism and 
hyperchromatism. Architectural changes include crowding of tubules and villiform 
surfaces. The severity of architectural and cytological changes differentiates low 
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and high grade dysplasia. However it is often difficult to identify dysplasia due to 
various reasons which include inadequate samples, sampling error and low inter-
observer agreement (IDA) among histopathologists. The IDA for LGD is less than 
50%, but this improves significantly in cases of HGD 112, 113. The natural history 
of dysplasia in terms of progression to cancer is less well understood. 
1.2.4 Preventive strategies for developing Barrett's oesophagus 
The greatest morbidity with Barrett's oesophagus is development of oesophageal 
adenocarcinoma. It is unclear at what stage does Barrett's oesophagus occur in the 
natural history of reflux disease. There is no convincing evidence to suggest that 
regular medical treatment ofGORD will prevent occurrence of Barrett's. This is 
also difficult to ascertain as in most of the cases, Barrett's is diagnosed on the first 
endoscopy in patients with symptoms of reflux disease. 
Chemoprevention as the way to reduce development of dysplasia and 
adenocarcinoma has been widely studied. Regular use of Aspirin and non-steroidal 
anti-inflammatory drugs (NSAIDS) were found to influence the progression in 
epidemiological studies. One of the earliest case-control studies looked at patients 
diagnosed with oesophageal adenocarcinoma, squamous carcinoma, cardia 
adenocarcinoma and non-cardia gastric cancers as cases. The study was controlled 
for major co-morbidities and they found that current use of aspirin is associated 
with reduced OA (OR 0.37), oesophageal squamous cancers (OR 0.49) and non-
cardia gastric cancers (OR 0.46). There was no protection noted for cardia 
adenocarcinoma. There was a similar reduced risk with current use ofNSAIDS as 
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well in this cohort 114. An American epidemiological study from databases such as 
National Health and Nutrition Examination Survey (NHANES J) and the National 
Epidemiologic Follow-up Studies (NEFS) found that occasional usage of Aspirin 
and NSAIDS is associated with a 90% reduction in OA occurrence and none of 
the regular users developed cancer in the 12-16 year follow up 115. A more recent 
study using Barrett's animal models found beneficial effects of chemoprevention 
with selective and non-selective cyclo-oxygenase 2 inhibitors (COX 2) 116. 
However prospective studies using COX-2 inhibitors did not show any 
commendable effect of chemoprevention on development of ~ A . . A study by 
Heath et al called 'chemoprevention for Barrett's oesophagus trial' (CBET), 
included more than 200 patients with Barrett's oesophagus with low and high 
grade dysplasia in a phase II trial. They were randomised to receive Celecoxib or 
placebo. The primary outcome measure was change in proportion of biopsy 
specimens with dysplasia after 48 weeks of treatment. No statistically significant 
difference was seen between the groups. There was a suggestion that the lack of 
effect could have been due to the low doses ofCelecoxib used (200 mg BD) 117. 
The data on use of PPJ as chemo protective agents to prevent dysplastic 
progression of Barrett's is also controversial. PPI is widely used in patients with 
Barrett's and the theoretical basis for this is the fact that acid exposure induces 
proliferation of cells and facilitates apoptosis. Considering the fact that acid reflux 
is thought to be a factor in developing intestinal metaplasia, PPJ use seems 
sensible in the absence of any prospective controlled trials showing benefit 118. 
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Nevertheless, some observational studies suggest some benefit ofPPI in the 
progression of Barrett's to cancer 119. A recent prospective cohort study also 
suggested a reduced risk of progression to HGD/cancer on regular PPI use 120. 
1.2.5 Surveillance strategies in Barrett's oesophagus 
Endoscopic surveillance programme has been recommended in Barrett's 
oesophagus in the absence of any definitive preventive strategies and hoping that 
this would pick up early cancers and thus improve the outcome compared to 
symptomatic cancers. The reported annual incidence of cancer in BO is variable 
ranging from 0.1 to 2.0%. A recent Danish population based study in a cohort of 
11,208 patients with Barrett's oesophagus from 1992 to 2009 found that the 
absolute annual risk for Barrett's cancer was 0.12% which is much lower than the 
widely described 0.5% 121. However, there are concerns that there is a significant 
regional variation in developing Barrett's cancers in the western world. A meta-
analysis including studies from United Kingdom suggested that the conversion 
rate form non-dysplastic Barrett's to adenocarcinoma is around 1% 122. The 
prognosis of patients with advanced oesophageal adenocarcinoma who are treated 
with surgery remains poor at 10% five year survival rate 123. Also, surveillance 
detected cancers are at a much earlier stage than symptomatic cancers which also 
have an impact on the survival rates of patients. In a meta-analysis, there was 
significantly improved survival in patients under surveillance at I year (88% Vs 
67%) and at 5 years (80% Vs 31%) compared to symptomatic cancers 124. This 
finding led to the suggestion of regular surveillance in Barrett's oesophagus by 
most national gastroenterological societies ranging from every 2-3 years. The 
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patients who are in a surveillance programme tend to be younger and generally in 
good health compared to those presenting with oesophageal adenocarcinoma. 
Thus controversy exists as to whether regular surveillance would reduce mortality 
from Barrett's cancer 125. There are currently no studies that have addressed the 
issue whether the mortality from Barrett's cancer has reduced due to regular 
surveillance. 
1.2.6 Endoscopic imaging techniques used in Barrett's surveillance 
Endoscopic surveillance is usually done using white light endoscopy for 
assessment of any abnormal nodular lesions in BO followed by targeted and 
random four quadrant biopsies every 1-2 cm of the Barrett's length 126. This is 
associated with significant sampling error as only 5-10% of the mucosal surface 
may be mapped 127. In tum this has resulted in low yield of dysplasia in routine 
sampling questioning the role of regular Barrett's surveillance. Age and co-
morbidities are important factors to consider before enrolling patients for regular 
surveillance. 
The primary aim of regular surveillance is to identify early neoplastic changes 
such as dysplasia or early cancer which could then be treated expecting a better 
outcome compared to those with symptomatic cancers. While there is no evidence 
to suggest that regular surveillance reduces cancer related mortality, there is 
suggestion to limit surveillance to population at high risk. This includes patients 
who are> 45 years old, male sex, Barrett's segment> 8 cm, long duration of 
reflux symptoms and presence ofuIceration or stricture 128. The early neoplastic 
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lesions are often subtle and difficult to identify with white light endoscopy. Hence 
various image enhanced techniques are described to improve dysplasia detection 
129. This includes chromoendoscopy, narrow band imaging, autofluorescence 
imaging, electronic chromoendoscopy and confocal endomicroscopy. These 
techniques are described in detail in section 1.1. 
The photons interact with the tissue by elastic scattering or absorption which is 
wavelength dependent 125. Raman spectroscopy is based on the fact that some of 
the photons set up molecular vibrations and will provide molecular fingerprint for 
the identification of dysplasia and cancer 130. An endoscopic probe is developed 
for in-vivo diagnosis; however this remains mostly a research tool 131. 
1.2.7 Molecular markers in Barrett's oesophagus 
Various genes and molecular biomarkers are identified in BO and the knowledge 
about these genetic changes in non-dysplastic Barrett's and adenocarcinoma could 
throw light into the molecular pathways of progression ofBO. 
Genetic instability induced by allelic loss, changes in DNA methylation and 
ploidy abnormalities are described in BO. One of the common genetic alterations 
in oesophageal adenocarcinoma is loss of heterozygosity (LOH). LOH at 
chromosomes l7p and 9p are the earliest alterations noted in BO. LOH at 3p21, 
5q21, 9p21 and 17p 13 chromosomal regions in non-dysplastic BO were found to 
be useful biomarkers for individuals with high risk of developing adenocarcinoma 
132. Various chromosomal changes include trisomy of chromosome 7 and 18, or 
loss of the Y chromosome 133,134. 
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Widespread DNA changes occurring during malignant transfonnation of Barrett's 
to adenocarcinoma included ploidy abnonnalities such as tetraploidy and 
aneuploidy. In patients with HGD and OA, 90% were found to have ploidy 
abnonnalities. It is thought that increased ploidy alterations progress the 
development from HGD to OA. On the other hand tetra and aneuploidy were also 
detected in non-dysplastic BO 135.136. The earliest and most common genetic 
alterations in 80 are LOH at 17p and 9p followed by tetraploidy and aneuploidy. 
The life span ofnonnal cells is closely related to the telomere length and 
telomerase activity. Nonnally cells undergo telomerase shortening during cell 
cycle which in tum induces cell senescence. However, in neoplastic cells this 
activity is altered and the telomere length is maintained which in tum leads to cell 
immortalisation 137. Telomerase activity is associated with upregulation of human 
telomerase reverse transcriptase expression (hTERT) and high levels oftelomerase 
and hTERT expression are seen in OA than patients without cancer 138. 
In patients with GORD and Barrett's, one of the most important hyper 
proliferative cell stimuli is gastric acid and bile acid. The most common and well 
described proliferation marker is Ki67and proliferating cell nuclear antigen 
(PCNA). Suppression of acid exposure is found to induce cell differentiation and 
reduce cell proliferation 139. 
The p53 gene which is located on chromosome 17p is very commonly altered in 
human cancers. Alterations in p53 are associated with mutations and LOH and are 
well documented in Barrett's oesophagus. It was noted that p53 mutations are seen 
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1-5% non-dysplastic Barrett's, 65% in LGD, 75% in HGD and 50-90% in OA 140. 
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1.2.8 Management of Barrett's oesophagus 
1.2.8.1 Medical management of Barrett's oesophagus 
The medical management in Barrett's is primarily treatment of associated GORD 
with proton pump inhibitors. There is no controlled trial to prove that use of PPJ 
will reduce cancer progression in Barrett's oesophagus even though it is well 
known that gastric and bile acid reflux induces hyper proliferation, suppress 
apoptosis and promote carcinogenesis. In vitro studies using biopsy specimens 
from patients with 80 at baseline and after 6 months of PPJ therapy were found to 
have reduced expression of proliferating cell nuclear antigen (peNA) and 
increased expression of a differentiation factor ViIIin, in those treated with acid 
suppression 142. The overall benefit of using PPJ in patients with BO and no 
evidence of reflux, with a view to prevent progression to cancer, needs to be 
discussed individually weighing the benefit and risk. 
Use ofPPIs is beneficial to reduce symptoms ofGORD in patients with Barrett's 
Oesophagus. Ph studies have shown persisting reflux in patients who were 
rendered asymptomatic on PPIs 143. Patients with BO were considered to have 
resistance to anti-reflux therapy. This could be due to severe reflux rather than a 
true resistance to the anti-reflux properties of PPJ therapy. A randomised cross 
over trial used 3 different doses of esomeprazole in patients with Barrett's. All 
three doses significantly reduced the intragastric acidity but in 16-23% of patients, 
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the oesophageal acid exposure continued 144. The reflux diathesis is very strong 
that whatever acid in the stomach produces reflux. 
A randomised controlled study showed partial regression of Barrett's with 
aggressive anti-reflux therapy. 68 patients with BO and ongoing reflux were 
enrolled to receive Omeprazole 40 mg BO or Ranitidine 150 mg BO. Reflux 
symptoms improved in both groups, but Omeprazole arm showed a statistically 
significant but small regression in length of Barrett's 145. Whether these findings 
are a simple representation of changes in size of hiatus hernia or due to an inter-
operator observation bias needs to be debated. 
The role of anti-reflux surgery in regression of Barrett's and preventing 
development of oesophageal adenocarcinoma has been suggested mainly in 
uncontrolled trials. A systematic review of 25 studies showed regression of 
Barrett's and dysplasia with anti-reflux studies, but the evidence for reduction in 
incidence of adenocarcinoma was mainly from uncontrolled studies 146. 
1.2.S.2 Endoscopic resection of Barrett's neoplasia 
Endoscopic resection (ER) could be offered as a therapeutic option in patients 
presenting with focal HGO and mucosal cancer. Those with submucosal invasion, 
vascular or lymphatic invasion should be referred for oesophagectomy. However, 
low risk submucosal invasion (T I sm I) is considered to be appropriate for 
endothcrapy in many centres 147. ER is considered to be therapeutic if lateral and 
deeper margins are clear of the tumour. Clearance of lateral margins is 
histologically difficult to assess, especially in cases of piecemeal resection. This is 
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usually achieved by making sure that all the marked areas are removed at the time 
of resection and follow up endoscopies are clear. 
A large series published by the Wiesbaden group showed a complete remission of 
Barrett's cancer in 95% of patients treated with ER alone at 5 years follow up. A 
significant proportion of patients (20%) developed metachronous lesions during 
follow up, which were all managed endoscopically. The calculated 5 year survival 
rate was 84% 148. Stepwise radical endoscopic resection (SRER) to remove the 
entire segment of dysplastic Barrett's was attempted in another study. In 34 
patients treated, all had complete eradication ofHGD/early cancer and majority of 
them had complete eradication of Barrett's epithelium. However, a significant 
proportion of patients developed dysphagia secondary to stricture, which were all 
managed endoscopicallyl49. Two patients in this cohort developed perforations. 
Considering the higher rate of complications, SRER could not be recommended in 
all patients, except in those with short segment dysplastic BO. ER could be 
performed using an EMR-cap technique or a multi-band Mucosectomy device 
(MBM). 
M ultiband M ucosectomy kit (Duette®-Cook Medical, Bloomington, IN) includes 
a modified multiband ligator and a hexagonal polypectomy snare measuring 1.5 to 
2.5 cm made of braided wire. The device is attached to the endoscope as in case of 
variceal ligation technique. The advantage is that multiple resections could be 
achieved. This is particularly useful in flat dysplasia, where a pseudo-polyp is 
formed by banding and this could be easily resected. 
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The use of a transparent distal attachment and suction, following local injection of 
saline to produce an elevation of the mucosal lesion, offers several significant 
advantages over alternative techniques, including secure, slip-free capturing of the 
target mucosa, and resection of a wider area at one time. This is the EMR cap 
technique. The distal attachment has an internal rim that allows easier positioning 
of the diathermy snare prior to resection. A straight cap and an oblique cap are 
available. A combination of Gelofusine, adrenaline and indigocarmine is useful 
for lifting the lesion; however saline in itselfis used by many endoscopists. The 
EMR cap is especially useful for an en-bloc resection of a raised lesion. A 
comparison between these two techniques was done in 40 patients (80 resections) 
by the Amsterdam group. The time taken for procedure was significantly lower 
using a MBM kit, while the specimens were smaller in size with MBM compared 
to the EMR cap technique. The incidence of bleeding was also lower in the MBM 
group, and one perforation occurred with EMR cap. Multiband mucosectomy is, 
therefore, most suited for en-bloc resection of lesions smaller than 10 mm or for 
'd d . ffl 150 151 WI esprea resectIOn 0 at mucosa . . 
1.2.8.3 Endoscopic ablative therapies 
Various ablation therapies are used to treat non-dysplastic and dysplastic Barrett's 
oesophagus. Thermal ablation therapies are the most commonly used which 
include multipolar electrocoagulation (MPEC), argon plasma coagulation (APC) 
and more recently radiofrequency ablation (RF A). MPEC is a contact ablation 
technique using an electrode passed through the accessory channel of the 
endoscope. Initial studies showed promise in ablating non-dysplastic BO with 
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reversal of Barrett's epithelium. The studies used concomitant acid suppression 
after ablation 152,153. 
APe is a non-contact thermal technique using a probe passed through the 
accessory channel of the scope. The probe is usually placed 1-1.5 mm away from 
the mucosal lining before applying the thermal energy. 70 patients underwent high 
power APe ablation (90 W) of non-dysplastic BO followed by strong acid 
suppression with proton pump inhibitors. 69 treated patients had a complete 
squamous degeneration after a mean of 2 APe sessions and 12 months follow up 
154. After a 5 years follow up only 12% patients had evidence of intestinal 
metaplasia during surveillance endoscopies giving a histological relapse rates of 
3% per year 155. APe was also used to treat patients with Barrett's HGD 156. 
Twenty nine patients with HGD underwent APe ablation and 86% responded to 
treatment. Over a follow up period of 7 years, 22 patients had a compete 
. . h . h I' 157 regression Wit neo-squamous eplt e mm . 
Radiofrequency ablation is a relatively new technique for eradication of non-
dysplastic and dysplastic Barrett's. There are 2 different catheters available. One is 
a balloon based system (HAL0360) and the other one is a paddle which could be 
attached to the tip of the scope (HAL090). HAL0360 is used for circumferential 
ablation of Barrett's using closely packed electrodes distributed circumferentially 
over a 3 cm long balloon and delivering a short burst of energy. HAL090 is useful 
for focal ablation of residual Barrett's or islands 158. 
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A randomised, sham-controlled trial investigated the efficacy ofRFA in 
eradicating Barrett's dysplasia and preventing progression of disease. This study 
included 127 patients, 64 with low-grade dysplasia (LGD) and 63 with high-grade 
dysplasia (HGD), from 19 different centres in the USA. Complete eradication of 
dysplasia was achieved in 86% (92% for per protocol analysis) with no statistical 
differences between the LGD and HGD groups. Total eradication of SIM was 
achieved in 77% (83% for per protocol analysis), again, irrespective of the grades 
of dysplasia 159, Various other uncontrolled trials have also shown that RFA is safe 
and efficacious in eradicating dysplasia and intestinal metaplasia 160,161. A 
systematic review including 9 studies and 429 patients, found that complete 
eradication of Barrett's dysplasia and metaplasia was achieved respectively for 71-
100% and for 46-100% of the patients. There were no serious adverse events 
reported and buried glands were noted only in one case 162, 
Photodynamic therapy was one of the first ablative therapies used for Barrett's 
dysplasia 163.164, This technique involves intravenous administration of a 
photosensitising agent such as porfimer sodium many hours before the endoscopy 
165. A laser light is used through a fibre passing through the accessory channel of 
the endoscope to activate the photosensitising agent to achieve ablation in 
Barrett's oesophagus 166,167. A randomised trial compared PDT with Omeprazole 
in patients with Barrett's HGD. The PDT arm was successful in eradicating 
dysplasia in 77% as opposed to Omeprazole which eradicated dysplasia in 39% 
168, The significant drawbacks of this modality are stricture formation and 
photosensitisation. 
64 
1.2.8.4 Surgical management of Barrett's neoplasia 
Oesophagectomy is the only definitive treatment which clearly removes the all 
neoplastic epithelium along with adjacent lymph nodes. However, 
oesophagectomy is associated with significant morbidity and mortality compared 
to other less invasive endoscopic therapies such as endoscopic resection and 
ablative therapies. A Dutch study suggested that the mortality improves with 
increasing number of surgeries performed by the hospital and thus suggesting 
centralisation of services 169. The patient needs a 10-15 days hospital stay after 
surgery and up to 30% patients develop at least one serious complication such as 
pneumonia, myocardial infarction, heart failure or anastomotic leak 170. The 
improvement in healthcare has resulted in significant reduction of morbidity 
which still remains substantial. The long term problems include dysphagia, weight 
loss and chronic GORD. Minimally invasive oesophagectomy tends to have lesser 
hospital stay but morbidity and mortality depends on the expertise. 
1.2.9 How to improve outcome in patients with Barrett's 
oesophagus 
The previous discussions have made it clear that dysplasia in Barrett's oesophagus 
progresses in a stepwise manner progressing through low grade dysplasia, high 
grade dysplasia and finally oesophageal adenocarcinoma. The only management 
strategy in the absence of any definitive preventive measures, either by medical or 
surgical measures, is to detect neoplasia early and treat accordingly. The 
surveillance strategy by doing four quadrant random biopsies every 2 cm is 
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associated with sampling error and the yield of dysplasia is sub-optimal. In this 
setting, image enhanced endoscopy techniques might provide additional benefit in 
terms of identifying and targeting dysplasia during surveillance. This thesis will 
address the value of multi modal imaging during Barrett's surveillance 
endoscopies. 
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CHAPTER 2 
AIMS 
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1. To determine the role of high definition endoscopy, narrow band imaging 
and autofluorescence imaging in detection of dysplasia in Barrett's 
oesophagus 
2. To determine whether autofluorescence imaging technique has sufficient 
inter-observer reliability in Barrett's surveillance 
3. To determine the biological basis of autofluorescence and the role of 
collagen and elastin in autofluorescence 
4. To develop an objective measurement of autofluorescence to reliably 
identify dysplasia in Barrett's oesophagus 
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CHAPTER 3 
HIGH DEFINITION VERSUS STANDARD 
DEFINITION WHITE LIGHT ENDOSCOPY FOR 
DETECTING EARLY NEOPLASIA IN BARRETT'S 
OESOPHAGUS SURVEILLANCE 
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3.1 Abstract 
Introduction 
High definition (HD) endoscopy systems provide superior image resolution 
compared to the older standard definition (SO) endoscopy systems. However, the 
utility of this new technology in dysplasia detection during Barrett's surveillance 
has not been evaluated. 
Aims and Methods 
The aim was to assess whether using HO endoscopy system translates to better 
outcomes compared to the SO system in terms of detecting dysplastic lesions in 
patients with Barrett's oesophagus (BO) undergoing surveillance. 
A retrospective cohort study of patients with non-dysplastic BO undergoing 
surveillance endoscopy with biopsies was performed. Data was retrieved from the 
central hospital electronic database. Procedures performed for non-surveillance 
indications; BO Prague COM 1 classification with no specialised intestinal 
metaplasia (SIM) on histology; patients diagnosed with dysplasia or cancer on 
index endoscopy and procedures where any other advanced imaging techniques 
was used were excluded from the study. Logistic regression was performed to 
estimate adjusted odds ratios (aOR) and 95 % confidence intervals (CI) comparing 
outcomes with SD and HD systems. 
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Results 
The HD system was superior to the SD system in targeted detection of dysplastic 
lesions (aOR 3.27, 9S% CI 1.27-8.40) as well as all dysplasia detected on random 
and target biopsies (aOR 2.36, 9S% CI I.S0-3.72). More false positive lesions 
were detected with the HD system (aOR 1.16, 9S% CI 1.01-1.33) and it had a 
marginally higher yield of dysplasia on random biopsies alone (aOR 1.07, 9S% CI 
1.00-1.15). There was no difference between HD and SD in diagnosing all 
(random and target) high grade dysplasia (HGD) or cancers (aOR 0.93, 95% CI 
0.83-1.04). 
Trainee endoscopists, number of biopsies and male sex were all significantly 
associated with a higher yield of dysplastic lesions. Trainees were also more likely 
to detect false positive lesions (aOR 5.26, 95% CI 2.11-13.1S) compared to non-
trainees. 
Conclusions 
The use of the HD endoscopy system is associated with better targeted and any 
dysplasia detection during BO surveillance. HD endoscopy cannot replace random 
biopsies during BO surveillance. 
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3.2 Introduction 
The advances in electronics over the past few decades have improved the 
endoscopic resolution and definition considerably. The standard definition signals 
offer images in a 4:3 aspect ratio with image resolutions up to 700 X 525 pixels. 
SO endoscopes are equipped with CCOs that produce an image signal of 100,000 
to 400,000 pixels. Advances in the technology have resulted in smaIIer chips with 
higher number of pixels in the CCO which can offer images with resolutions that 
range from 850,000 to over a million pixels 3. These are called high resolution 
endoscopes. The images generated from such endoscopes are viewed on high 
definition television transmitted via HO cables to obtain the HO endoscopy 
systems. This would improve the mucosal details seen on the monitor and could 
potentially improve detection of early neoplastic lesions in BO. 
A prospective randomised cross-over trial comparing high resolution endoscopy 
(HRE) with indigocarmine or narrow band imaging (NBI) showed that most 
patients with HGD or early cancer could be identified by high resolution 
endoscopy alone with no additional advantage from chromoscopy or NBI 16. 
Similarly an inter-observer study using high resolution endoscopy, chromoscopy 
and NBI suggested that addition of enhancement techniques did not improve the 
yield of dysplasia compared to HRE alone 21. A more recent randomised study 
compared endoscopic trimodal imaging (ETMI) with SO endoscopy and found 
that ETMI is superior to SO in targeted detection of Barrett's dysplasia 171. All 
these studies are performed in an enriched population with high incidence of 
dysplasia and not on routine surveillance population. Moreover these studies are 
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from a few centres of excellence. It is difficult to extrapolate this data to the 
general surveillance population. There is no data comparing standard definition to 
high definition endoscopy in BO surveillance and thus the aim of this study was to 
compare the HD and SD systems in detecting dysplasia during Barrett's 
surveillance 
3.3 Material and methods 
3.3. t Data collection 
The data for this study was retrospectively collected from the endoscopic and 
clinical database at Nottingham University Hospitals. Clinical and demographic 
data of all patients undergoing Barrett's surveillance between September 2008 and 
August 2012 were reviewed. All patients over the age of 18 years undergoing 
surveillance endoscopy and biopsy for Barrett's oesophagus were included. The 
exclusion criteria were, BO with Prague COM 1 classification with no SIM on 
histology; patients diagnosed with dysplasia or cancer on index endoscopy; 
procedures where any other advanced imaging techniques was used; non-
surveillance endoscopies and patients with no histological confirmation. 
Patient data including age, sex, diagnosis, length of Barrett's C&M classification, 
any visible lesions, number of lesions, biopsies taken, whether targeted or random 
biopsies, endoscopic system used and grade of endoscopist (ie. consultant/trainee) 
were recorded. Endoscopies performed using a high resolution endoscope H260 
(Olympus-Keymed UK) using an Olympus Lucera Spectrum processor and an HD 
1080i capable monitor (Olympus OEV 191 H) were classified as high definition 
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endoscopies. All other procedures using endoscopes GIF Q230, XQ240, Q240, 
and Q260 were classified as standard definition endoscopies. During BO 
surveillance, targeted biopsies are taken in the presence of any identifiable 
mucosal abnormalities. This was followed by random biopsies from four 
quadrants every 2 cm as per the Seattle protocol 172. Biopsies were sent for 
histopathological analysis in 10% formalin, and they were reported according to 
Vienna classification as no dysplasia, indefinite for dysplasia, low grade dysplasia, 
high grade dysplasia and invasive cancer 173. 
3.3.2 Statistical analysis 
Logistic regression was performed to estimate odds ratios (ORs) and 95 % 
confidence intervals (CI) comparing outcomes with standard and high definition 
endoscopy (PASW version 19, IBM Corp). Separate regression models for (i) 
dysplasia detected on target biopsy; (ii) all high grade dysplasia/cancer; (iii) 
dysplasia detected on random biopsy alone; (iv) number of false positive lesions; 
and (v) all dysplastic lesions detected were performed. 
Statistical models included the following potential confounders, chosen a priori 
based on the literature: age at the index exam, sex, trainee endoscopist or 
consultant, length of Barrett's oesophagus and the number of biopsies taken. The 
goodness of fit for the logistic regression model was determined using the 
Hosmer-Lemeshow test 174, The collinearity between the confounder variables 
using correlation matrices was tested. If collinearity was detected (rho >0.6) we 
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planned to minimise this by inputting the variable separately in the multivariate 
analysis 
3.4 Results 
A total of 521 endoscopies were performed of which 266 were done using SO 
endoscopy systems in 227 patients undergoing Barrett's surveillance. 255 
endoscopies were performed in 208 patients using HO endoscopy systems during 
the study period. III endoscopies during the study period were performed using 
autofluorescence and narrow bad imaging (trimodal) and they were excluded 
(Figure 1). Patients with non-surveillance indications such as those for EMR, post 
EMR follow up and other therapeutic procedures were excluded. Patient 
demographics are shown in Table I. 
3.4.1 Dysplasia detection on target biopsies 
The total number of targeted biopsies taken in the HO arm was 51, and that in the 
SO arm was 20. There were a total of 6 dysplastic lesions identified on target 
biopsy in the HO group and 2 dysplastic lesions in the SO group. This included 4 
cancers and 2 LGO in the HO arm and 2 cases of indefinite for dysplasia (10) in 
the SO arm. The high definition endoscopy was superior to standard definition 
endoscopy in targeted detection of dysplastic lesions (aOR 3.27, 95% CI 1.27-
8.97) (Table 2) 
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Endoscopy rep0l1s and patient electronic records recorded as Barrett's 
smveillance were analysed: n=946 (SO=502, HD-333, EThn=111) 
perfol1ued on 0=580 patients dming the study period (Sep 2008-Aug 2012) 
N=314 procedmes were excluded 
No biopsies takenn=34 
Not for sluveillance indication n=37 
--. Known dysplasia n=41 
Cancer on index endoscopy n=22 
Wrongly coded and duplicates n=18 o 
Data collected on remaining n=632 procedm-es (SO=266. H0=255, EThU=III) 
perfolUled on n=460 patients 
f--+ 
EThil procedm-es n= III procedmes 
were excluded 
Data IDlalysis perfomled on remaining n=521 procedm-es (SO=266, HD=255) 
perfol1ned on u=435 patients (S0=227, HD=208) 
Figure 1: Flow chart of study procedures 
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Table 1: Demographic and clinico-pathological details of endoscopy 
procedures 
Variable Total n=521 HD group SO group 0=266 
0=255 
Age (mean ±SD) years 68.0 (11.9) 68.8 (12.1) 67.3 (11.7) 
Male sex (%) 356 (68.3) 166 (65.1) 190 (71.4) 
PPI users (%) 415 (84.5) 220 (88.7) 195 (80.3) 
Endoscopist grade 
Consultant 371 (71.2) 161 (63.1) 210(78.9) 
Trainee (GI fellow) 149 (28.6) 93 (36.5) 56 -(21.0) 
Barrett's Prague class 
C length (median, 30-5) 2 (0-4) 3 (1-6) 
IQR) 4 (2-6) 4 (2-6) 4 (2-6) 
M length (median, 
IQR) 
Hiatus hernia 327 (62.8) 172 (67.5) 155 (58.3) 
Oesophagi tis 89 (17.1) 48 (18.8) 41(15.4) 
SIM 379 (76.6) 178 (70.9) 201 (82.4) 
Target biopsies 71(13.6) 51(20) 20 (7.5) 
Random biopsies 481 (92.3) 238 (93.3) 243 (91.4) 
No. of random biopsies 8 (4-8) 4 (3-6) 4 (4-8) 
(median, IQR) 
Dysplasia on random 46 (8.8) 25 (9.8) 21 (7.9) 
biopsies (%) 
Any Dysplasia (random 53 (10.1) 31 (12.2) 23 (8.7) 
and target) (%) 
Total no. of lesions 23 (4.4) 18 (7.1) 5 (1.9) 
detected (%) 
No. of dysplastic lesions 8 (1.5) 6 (2.4) 2 (0.8) 
(dysplasia on target 
biopsy) (%) 
No. of false positive 15 (2.9) 12 (4.7) 3 (1.1) 
lesions (false positive on 
target dysplasia) (%) 
Any HGD/cancer 19(3.7) 15 (5.9) 4 (1.5) 
(random and target) (%) 
HO: High definition, SO; Standard definition, IQR: Inter-quartile range, SIM: 
specialised intestinal metaplasia, HGO: High grade dysplasia 
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Table 2: Logistic regression for all dysplasia detected on targeted biopsies 
Variable Odds Ratio 95%CI P value 
Total biopsies 1.43 1.22-1.68 < 0.001 
Male Gender 5.32 2.18-12.99 < 0.001 
Trainee 4.69 1.05-20.82 0.042 
HD Scope 3.27 1.27-8.39 0.014 
Barrett's length 0.98 0.85-1.15 0.872 
Age 1.07 1.05-1.1 <0.001 
.. CI-Confidence interval, HD-Hlgh defimtlOn 
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3.4.2 Dysplasia detection on random and targeted biopsies 
There were 25 endoscopies in the HO ann which detected dysplasia on random 
biopsies alone which included 2 cancers, 8 HGO, 11 LGD and 4 10 as compared 
to 21 endoscopies in the SO ann with dysplasia on random biopsies alone 
including 1 cancer, I HGO, II LGO and 8 10. The HO ann detected significantly 
more number of dysplasia by target and random biopsies combined together as 
compared to the SO ann (aOR 2.36,95% CI 1.50-3.72) (Table 3) 
High definition endoscopy identified significantly more number of dysplastic 
lesions when analysis was done excluding indefinite for dysplasia on random and 
target biopsies as compared to SO endoscopy (aOR 1.12,95% CI 1.04-1.2). 
However, there was no significant difference between HO and SO in detection of 
HGD or cancer on both targeted and random biopsies (aOR 0.93, 95% CI 0.83-
1.04) (Table 4). There was a marginally higher pick up of all dysplasia on random 
biopsies alone using HD endoscopy compared to the SO ann (aOR 1.0795% CI 
1.0-1.15) (Table 5). 
More number of false positive lesions was identified by HD endoscopy on target 
biopsies compared to SO (aOR 1.16,95% CI 1.01-1.33). On multivariate analysis, 
endoscopies perfonned by trainee endoscopists, number of biopsies taken and 
male sex were significantly associated with increased yield of targeted dysplasia 
(Table 2). Trainees also detected more number of false positive lesions compared 
to non-trainees (aOR 5.26 95% CI 2.11-13.16). 
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Table 3: Logistic regression for all dysplasia detected on random and 
targeted biopsies 
Variable Odds Ratio 95%CI 
Total biopsies 1.08 1.01-1.15 
Male Gender 3.58 2.32-5.52 
Trainee 1.77 0.99-3.16 
lID Scope 2.36 1.5-3.71 
Barrett's length 0.96 0.88-1.05 
Age 1.04 1.02-1.05 
CI-Confidence interval, lID-High definition 
P value 
0.017 
< 0.001 
0.053 
<0.001 
0.399 
<0.001 
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Table 4: Logistic regression for HGD/Cancer for random and targeted 
biopsies 
Variable Odds Ratio 95%CI P value 
Total biopsies 4.9 2.55-9.44 <0.001 
Male Gender 4.49 1.53-13.19 0.006 
Trainee 1.98 1.04-3.77 0.037 
HD Scope 0.93 0.83-1.04 0.174 
Barrett's length 1.31 1.17-1.46 <0.001 
Age 1.05 1.04-1.07 <0.001 
.. 
HGD-Hlgh grade dysplaSia, CI-Confidence mterval, HD-Hlgh defimtIOn 
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Table 5: Logistic regression for all dysplasia on random biopsies only 
Variable Odds Ratio 95%CI P value 
Total biopsies 3.96 2.49-6.29 <0.001 
Male Gender 1.72 0.93-3.18 0.082 
Trainee 2.79 1.71-4.56 <0.001 
HD Scope 1.07 1-1.15 0.50 
Barrett's length 3.96 2.49-6.29 <0.001 
Age 1.04 1.03-1.05 <0.001 
.. CI-Confidence interval, HD-Hlgh defimtIOn 
82 
3.5 Discussion 
This study compared the yield of dysplasia during Barrett's surveillance using 
high definition and standard definition endoscopy systems. The principal findings 
include a higher yield of any dysplasia in the HD arm. This was significant both in 
the targeted yield of dysplasia as well as combined targeted and random detected 
dysplasia. The number of random biopsies taken was similar in both arms, but the 
HD endoscopy facilitated more number of target biopsies. This could be due to the 
fact that HD images provide more detailed views of the Barrett's epithelium and 
subtle lesions were picked up. On the other hand, some of the inflammatory 
changes would have been more prominent on HD endoscopy thus leading to 
higher number of targeted biopsies. This is highlighted by the fact that there were 
higher false positive targeted biopsies in the HD arm. Nonetheless, this has led to 
increased dysplasia detection in the HD arm at the expense of more false positive 
lesions compared to SD endoscopy. A consensus statement on HOD in Barrett's 
oesophagus suggested the use of high resolution endoscopy in Barrett's 
surveillance with four quadrantic biopsies every 1-2 cm 175. The evidence itself for 
this recommendation was poor as there are no direct studies comparing HD V s 
SD. However, one of the studies compared SD endoscopy with NBI in 65 patients 
with Barrett's oesophagus where NBI identified more number of patients with 
dysplasia as well as higher grades of dysplasia compared to SD endoscopy 75. The 
NBI used in this study is a high resolution endoscopy system, but it is difficult to 
predict whether high resolution white light would deliver such results. 
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There was no difference in targeted or random detection of HOD and cancer 
between the HD and SD arm. This could be related to the small absolute number 
of HOD or cancer detected in the cohort as this was a surveillance population. Or 
else, this could be related to the fact that most HOD or early cancer lesions could 
be visualised with SD endoscopy itself and there is no additional role for HD 
endoscopy in this setting. 
Endoscopies performed by trainee endoscopists/fellows were found to detect more 
number of dysplasia compared to non-trainee endoscopists. This is a very 
interesting finding which could be explained in various ways. First of all, there is 
significantly more number of trainees/fellows who performed endoscopies in the 
HD arm (P<O.OO 1). Hence the increased dysplasia detection would be a result of 
better performance of HD endoscopy compared to the SD arm. However, we 
adjusted these findings for the type of endoscopy (HD Vs SD) and the results 
remain significant. Secondly, there was increased number of false positive lesions 
detected by trainees. This is due to overcalling dysplasia in this cohort thus 
leading to more number of targeted and overall biopsies. The other reason would 
be a higher representation of research fellows with interest in Barrett' oesophagus 
performing endoscopies compared to generalist non-trainee gastroenterologists. 
This would also relate to the more time spent on examination of Barrett's by the 
trainees/fellows compared to non-trainees. 
The other factor which improved dysplasia detection was the number of biopsies 
taken. This is an anticipated outcome as we are aware that there is significant 
sampling error in Barrett's surveillance biopsies. Hence, when more number of 
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biopsies is taken, it is likely to yield higher number of dysplasia, A retrospective 
study which analysed patients with Barrett's HGD/early cancer found that a 
significant number of patients undergoing surveillance did not have adequate 
number of biopsies taken, thus missing dysplasia during surveillance period and 
indicating sampling error 176. However, a more intensive Seattle protocol biopsies 
taken from every 1 cm of the Barrett's does not seem to reliably predict 
adenocarcinoma in patients undergoing oesophagectomy for HGD 177. This 
finding could not be extrapolated to non-dysplastic surveillance population and 
there is no evidence to suggest that a less intensive protocol is sufficient to 
identify any dysplasia. A significant number of dysplastic areas were detected by 
random biopsies alone and this indicates that HD endoscopy cannot replace 
random biopsies, Male sex was associated with higher yield of dysplasia, This is 
also an expected finding in the light of our knowledge that Barrett's 
d I 'af . h' h' I d ti I 178-181 ysp aSI cancer IS Ig er In rna es compare to ema es . 
There are various limitations associated with this study. The study was conducted 
using data collected retrospectively from the electronic case records and 
endoscopy reports of patients. In this setting it is difficult to standardise all the 
data, An ideal way of doing such a study would be a prospective randomised 
controlled study, However, the retrospective design could also be considered as 
strength. We have utilised actual clinical data of routine surveillance practice and 
this could represent a true picture as opposed to a clinical trial in controlled 
settings, It is also argued that endoscopists are naturally biased during a 
randomised trial and would perform endoscopies more diligently than in routine 
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clinical practice. As with all non-randomised trials, it is difficult to exclude all 
confounding variables; however appropriate statistical methods are used to adjust 
the variables within the limits of such a study. The other limitation for this 
retrospective study is that the endoscopists are not blinded to the clinical data and 
the pathologists are not blinded to endoscopy and clinical data. 
3.5.1 Conclusions 
In conclusion, the overall yield of dysplasia during Barrett's surveillance was 
better with HD endoscopy compared to SD endoscopy. HD endoscopy has 3 times 
higher chance of picking up targeted dysplasia compared to SD, which is at the 
expense of higher false positive lesions. There was no difference in detection of 
HGD or early cancer between the groups. Randomised controlled trials are 
necessary to examine these findings. It is difficult to recommend routine use of 
HD endoscopy for regular Barrett's surveillance based on these observations, but 
certainly should be considered as a valuable option. 
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CHAPTER 4 
NARROW BAND IMAGING FOR 
CHARACTERISATION OF HIGH GRADE 
DYSPLASIA AND SPECIALISED INTESTINAL 
METAPLASIA IN BARRETT'S OESOPHAGUS. A 
META-ANALYSIS 
Mannath J, Subramanian V, Hawkey CJ, Ragunath K. Endoscopy. 2010 May; 
42(5):351-9 
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4.1 Abstract 
Background 
Narrow band imaging (NBI), a novel endoscopic technique that highlights 
mucosal surface structures and microvasculature is being increasingly advocated 
as a too] to detect and characterise neoplasia and intestinal metaplasia in patients 
with Barrett's oesophagus (BO) 
Aim 
To assess the diagnostic accuracy ofNBI with magnification for the diagnosis of 
high grade dysplasia (HGD) and specialised intestinal metaplasia (SIM) in patients 
with BO. 
Methods 
A meta-analysis of studies which compared NBI based diagnosis ofHGD and 
SIM with histopathology as the gold standard was performed. 
Results 
Eight studies including 446 patients with 2194 lesions met the inclusion criteria. 
The pooled sensitivity, specificity, diagnostic odds ratio (DOR) and the area under 
the curve (AVC) for diagnosing HGD was 0.96 (95% CI 0.93-0.99), 0.94 (95% CI 
0.84-1.0),342.49 (95% CI 40.49-2896.89) and 0.99 (SE 0.0 I) on a per-lesion 
analysis and 0.95 (95% CI 0.88-1.0), 0.97 (95% CI 0.97-0.98), 343.45 (95% CI 
77.88-1514.70) and 0.99 (SE 0.01) on a per-patient analysis. For the 
characterisation ofSIM, the pooled sensitivity, specificity, DOR and AVC was 
0.95 (95% CI 0.87-1.0),0.65 (95% CI 0.52-0.78),37.53 (95% CI 6.50-217.62) 
and 0.88 (SE 0.08) on a per-lesion analysis and 0.97 (95% CI 0.94-1.0), 0.78 (95% 
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CI 0.56-1.0), 100.97 (95% CI 33.62-303.22) and 0.97 (SE 0.02) on a per-patient 
analysis. 
Conclusion 
NBI with magnification is accurate with high diagnostic precision for diagnosis of 
HGD in BO using irregular mucosal pit patterns and/or irregular microvasculature. 
NBI has high sensitivity but poor specificity for characterising SIM. 
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4.2 Background 
Barrett's Oesophagus is a complication of long standing gastro-oesophageal reflux 
disease (GORD) and is known to affect 10-15% of those with GORD. Patients 
with BO have a 30-125 times higher risk of developing adenocarcinoma compared 
to the general population 182. BO is characterised by endoscopically identifiable 
'salmon' coloured columnar epithelium containing specialised intestinal 
metaplasia (SIM) 182,183. The metaplastic epithelium accumulates genetic changes 
over a period of time and can progress through low grade dysplasia (LGD), high 
grade dysplasia (HGD) and then to oesophageal adenocarcinoma (OA) 184. Early 
dysplastic lesions can be endoscopically resected or ablated. This will reduce the 
risk of progression without the need for radical surgery with its associated 
morbidity and mortality 159. 
Regular surveillance of BO with random 4 quadrant biopsies every 1-2 cm is the 
standard practice, however the yield of dysplasia with such an intensive 
endoscopic biopsy protocol is suboptimal 185,186. Chromoendoscopy with 
methylene blue, crystal violet, acetic acid and indigocarmine has been advocated 
to improve the yield of intestinal metaplasia and dysplasia. However 
chromoendoscopy with methylene blue was found to be no better than random 
biopsies in a recent meta-analysis 38. Narrow band Imaging (NBI), a novel 
endoscopic technology, uses narrowed bandwidths of blue (440-460nm) and green 
(540-560nm) light waves with the help of a special filter that deletes the red light 
spectrum from the emitted light 71, This facilitates delineation of surface pit 
patterns and micro-capillaries, and by assessing their changes, it is possible to 
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identify abnormal areas and target biopsies accordingly. The filter is activated 
electronically by pressing a switch on the hand control and the endoscopists can 
easily switch between white light and NBI. It offers simi1ar benefits in terms of 
characterisation to magnification chromoendoscopy, but without the need for dye 
spray. NBI is widely used in characterisation of lesions in colon, oesophagus and 
lungs with high in-vivo diagnostic precision 187. 
Observational studies using NBI and magnification have identified various micro-
structural and capillary patterns in Barrett's oesophagus. Regular micro-structural 
patterns inc1ude round, linear, tubular or vi11ous/ridged type. Irregular patterns and 
absent pit patterns are also reported. Micro-vascular patterns are c1assified either 
regular or irregular. Sensitivity and specificity of the irregular micro-vascular and 
micro-structural patterns for prediction ofHGD was as high as 90 and 100% in a 
recent study 188. Similarly the villous/ridged/absent pit patterns were thought be 
highly suggestive of specialised intestinal metaplasia (SIM) and the round patterns 
associated with columnar lined epithelium. 
The aim of this meta-analysis is to assess the diagnostic accuracy, sensitivity and 
specificity ofNBI with magnification in characterising HGD and SIM associated 
with BO. 
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4.3 Methods 
4.3.1 Selection of studies 
We included all studies assessing the accuracy of narrow band imaging with 
magnification (NBI-Z) for characterising dysplasia or SIM in BO. Histology from 
the area of interest is used as the gold standard. The inclusion criteria were 1) 
prospective clinical studies where NBI-Z is used to assess BO 2) typical mucosal 
pit patterns and vascular patterns of the assessed areas are described 3) diagnostic 
accuracy in terms of sensitivity and specificity of mucosal patterns are compared 
against gold standard and 4) real time assessment of lesions or post hoc digital 
images characterisation is used. Studies using NBI for detection of lesions in BO 
without lesion characterisation and those with no extractable data were excluded. 
Also, studies without histological confirmation of lesions were excluded as were 
case reports, editorials, commentaries and data reported as abstracts only. 
4.3.2 Search strategy 
Bibliographical searches were performed up to June 2009 in MEDLINE, 
EMBASE, Web of Science, Google Scholar and Cochrane library using search 
terms 'Narrow Band Imaging' and 'Barrett's oesophagus'. Articles in all 
languages were included. We also searched for any abstracts from international 
conferences and hand searched references from published articles. Two 
investigators independently searched the databases and studies which were 
duplicated, reviews and case reports were excluded. 
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Relevant study abstracts from 
MEDLrnE screened (n=42) 
No other relevant studies identified Reviews. case reports and other 
from EMBASE, Google Scholar. non-clinical studies excluded 
Web of Science and Cochrane (n=29) 
library 
Studies retrieved for detailed evaluation 
(n=13) 
5 studies with no extractable data 
• were excluded 
8 studies with extractable datafor 
high grade dysplasia (HGD)or 
specialized intestinal metaplasia 
(SIM) on a per-tesion/ per-patient 
basis were used for meta-analysis 
Figure 1: Flow chart of study selection for meta-analysis 
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4.3.3 Data extraction and assessment of study quality 
All included studies were assessed by two reviewers independently and data 
extracted using a predefined data extraction fonn. The following variables were 
assessed; author, year of publication, publication fonnat, type of study, number of 
centres, endoscopes used, number of endoscopists and whether pit 
patterns/microvasculature was used to characterise lesions. True positives, false 
positives, false negatives and true negatives were extracted using histology as gold 
standard. The data were extracted both on 'per-patient' and 'per-lesion' basis 
wherever available. Where studies reported mucosal pattern and micro-vascular 
characteristics, the measures with highest accuracy was used for the overall 
analysis. 
The quality of the studies was assessed using the "Quality Assessment of 
Diagnostic Accuracy Studies" (QUADAS) tool 189. The tool is based on 14 item 
questionnaire summarised in Table 1, which should each be answered "yes," "no," 
or "unknown." The tool does not incorporate a global quality score 189. Quality 
assessment of studies was done independently by two reviewers and discrepancies 
in the interpretation were resolved by consensus (table 1). 
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Table 1: 'Quality Assessment of Diagnostic Accuracy Studies' (QUADAS) 
Author 1 2 3 456 7 8 9 to II 12 13 
Kara et.al N y y y y y y y y U u N y 
Kara et.al N y y y y y y y y y y y y 
Shanna et. al N N Y Y Y Y Y Y Y Y Y Y Y 
Curvers et.al N Y Y Y Y Y Y Y Y Y Y Y Y 
Singh et.a/ Y Y Y Y Y Y Y Y Y U Y Y Y 
Goda et.al N Y Y Y Y Y Y Y Y U y y y 
Anagnostopou]os N y Y Y Y Y Y Y Y Y y y u 
et.al 
Hamamoto et.al u Y u u u Y Y y N u u N u 
Y - yes; N - no; U - unknown. 
\. Was the spectrum of patients representative of the patients who will receive the test in practice? 
2. Were selection criteria clearly described? 
3. Is the reference standard likely to classify the target condition correctly'? 
4. Is the period between reference standard and index test short enough to be reasonably sure that the target condition did not 
change between the two tests? 
S. Did the whole sample or 8 random selection of the sample receive verification using a reference standard? 
6. Did patients receive the same reference standard regardless of the index test result? 
7. Was the reference standard independent of the index test (i.e., the index test did not form part of the reference standard)? 
8. Was the execution of the index test described in sufficient detail to permit replication of tile test? 
9. Was the execution of the reference standard described in sufficient detail to permit its replication? 
10. Were the index test results interpreted without knowledge of the results of the reference standard? 
I \. Were the reference standard results interpreted without knowledge of the results of tile index test? 
12. Were the same clinical data availahle when test results were interpreted as would be available when the test is used in practice? 
13. Were uninterruptable/intermediate test results reported? 
14. Were withdrawals from the study explained? 
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14 
Y 
Y 
Y 
Y 
u 
y 
u 
u 
4.3.4 Data synthesis 
Data analysis was perfonned using the Meta-Disc (version 1.4) software 190. 
Sensitivity and specificity were used as measures of diagnostic accuracy ofNBI in 
differentiating HGD and SIM. These were computed using a two-by-two table 
with NBI based diagnosis of high grade dysplasia by irregular pit patterns ± 
irregular vascular patterns and diagnosis of SIM with ridge/villous/absent pit 
patterns with regular microvasculature plotted against targeted histology as gold 
standard. Sensitivity (true positive rate [TPRD is defined as the proportion of 
sites/patients dctermined to be having HGD or SIM based on NBI correctly to the 
reference standard histology. Specificity (True negative rate or I-false positive 
rate [FPR D is defined as the number of sites/patients who are identified as not 
having HGD/SIM on NBI correctly compared to the reference standard. 
Forest plots were fonnulated to display estimates of accuracy and examine the 
heterogeneity of the summary measures of sensitivity and specificity by random-
effect model with correction for over dispersion. The joint distribution ofTPR and 
FPR is summarised with a summary receiver operating characteristic (SROC) 
curve. SROC curves used in analyses of diagnostic accuracy are intended to 
represent the relationship between TPR and FPR across studies when test 
performance is evaluated at varying diagnostic thresholds 191. Each study is a 
separate un it of anal ysis and contributes an estimate of TPR and FPR. Overall 
diagnostic performance of a test can be judged by the position and appearance of 
the SROC curve. The area under the curve (AVC) represents an overall summary 
measure of the curve and the test's overall ability to accurately distinguish cases 
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from non-cases. The Q* index, the highest point on the SROC curve that intersects 
the anti-diagonal, represents a summarisation of test performance where 
sensitivity and specificity are equal (so the probability of an incorrect test result is 
the same for cases and non-cases). An AVC of one represents perfect 
discriminatory ability, while a Q* index of one represents perfect accuracy 191. A 
value of 0.5 infers a test that is equally likely to diagnose a positive result as either 
positive or negative and most clinical tests have a value between 0.5 and 1.0. 
Likelihood ratios (LRs) state how many times more likely particular test results 
are in patients with disease than in those without disease. Positive LRs > 10 and 
negative LRs <0.1 provide convincing diagnostic evidence, whereas those >5 and 
<0.2 give strong diagnostic evidence 192. To calculate LRs, if the event of one of 
the cells of the cross table contained a zero value; 0.5 points were added to all the 
cells. 
Heterogeneity in meta-analysis refers to a high degree of variability in study 
results, a fairly common finding in diagnostic meta-analyses. Such heterogeneity 
could be due to variability in thresholds, disease spectrum, test methods, and study 
quality across studies. In the presence of significant heterogeneity, pooled, 
summary estimates from meta-analyses are not meaningful. A test for 
heterogeneity examines the null hypothesis that all studies are evaluating the same 
effect. The usual test statistic (Cochran's Q) is computed by summing the squared 
deviations of each study's estimate from the overall meta-analytic estimate, 
weighting each study's contribution in the same manner as in the meta-analysis. 
The test is known to be poor at detecting true heterogeneity among studies as 
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significant. Meta-analyses often include small numbers of studies and the power 
of the test in such circumstances is low. An alternative method is measuring 
inconsistency (f), which describes the percentage of total variation across studies 
that are due to heterogeneity rather than chance 193. We investigated the sources of 
heterogeneity using meta- regression and subgroup analyses. 
4.4 Results 
4.4.1 Description of studies 
The study selection process is summarised in Figure 1. After the initial screening 
(excluding case reports, reviews and other irrelevant articles by reading titles and 
abstracts) 13 studies were selected. A total of 8 prospective studies met the 
inclusion criteria either for a 'per-patient' or 'per-lesion' analysis or both 76,84,86, 
188,194-197. 5 studies were excluded 21,75,198-200 as there were no extractable data for 
calculations of sensitivity and specificity. Three of the excluded studies were 
inter-observer studies with no data available on true negatives or false positives to 
calculate sensitivity and specificity 21, 198, 199. Two other excluded studies were 
dysplasia detection studies and did not follow the mucosal morphological patterns 
for differentiation 75,200. Out ofthe 8 studies included, 6 studies gave details of 
HGD characterisation on per-lesion basis 76,84,86,188,194,195 and 4 studies yielded 
C • I' 76 84 188 195 6 d' d h .. f SIM data Jor per-patient ana YSls ' , , . stu 1es reporte c aractensatlOn 0 
on per-lesion basis 76,188,194-197 and 3 studies compared NBI based diagnosis of 
SIM on per-patient basis 76,188,195. The details of included studies are summarised 
in table 2. 
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4.4.2 Diagnostic accuracy ofNBI in HGD 
6 studies including a total of 1904 lesions in 377 patients were analysed for 
differentiation ofHGD lesions on per-lesion analysis. The pooled sensitivity and 
specificity were 0.96 (95% CI 0.93-0.99) and 0.94 (95% CI 0.84-1.0) 
respectively (figure 2). The pooled diagnostic odds ratio (DOR) was 342.49 (95% 
CI 40.49-2896.89) using a random effects model. As shown in figure 3, the area 
under the curve (AVC) was 0.99 (SE 0.01) with Q* of 0.95 (SE 0.02), indicating a 
high level of diagnostic accuracy ofNBI. The pooled positive LR was 15.248 
(95% CI 3.917-59.350) and negative LR was 0.75 (95% CI 0.040-0.141). 
On a per-patient analysis, 4 studies with 216 patients and 1616 lesions were 
pooled. The pooled sensitivity, specificity and DOR were 0.95 (95% CI 0.88-1.0), 
0.97 (95% CI 0.97-0.98) and 343.45 (95% CI 77.88-1514.70) respectively (figure 
4). The AVC and Q* were 0.99 (SE 0.01) and 0.95 (SE 0.02), again indicating the 
high accuracy ofNBI characterisation ofHGD on a per-patient basis as we1l 
(figure 5). 
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Figure 2: Pooled sensitivity and specificity ofNBI in diagnosing HGD on per-
lesion analysis 
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Figure 3: SROC curve of NBI in diagnosing HGD on per-lesion analysis 
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4.4.3 Diagnostic accuracy of NBI in SIM 
A total of 1938 lesions in 342 patients from 6 studies were used to analyse the data 
on characterisation ofSIM using NBI on a per-biopsy basis (figure 6). Pooled 
sensitivity and specificity were 0.95 (95% CI 0.87-1.0) and 0.65 (95% CI 0.52-
0.78) with a modest DOR of37.53 (95% CI 6.50-217.62). The AVC was 0.88 (SE 
0.08) and Q* was 0.80 (SE 0.08) which were lower compared to the diagnostic 
accuracy of characterising HGD (figure 7). Pooled Positive LR was 3.111 (95% 
CI 1.870-5.17) and negative LR was 0.107 (95% CI 0.26-0.44). 
3 studies with 210 patients and 1569 lesions were pooled to assess the accuracy on 
per-patient analysis (figure 8). Pooled sensitivity 0.97 (95% CI 0.94-1.0), 
specificity 0.78 (95% CI 0.56-1.0) and DOR 100.97 (95% CI 33.62-303.22) were 
similar to per-lesion analysis. The AVC and Q* were 0.97 (SE 0.02) and 0.92 (SE 
0.04) respectively (figure 9). The sensitivity ofNBI in differentiating SIM appears 
to be high; however the specificity is poor. 
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4.4.4 Heterogeneity of studies 
Studies used in HGD analysis: Heterogeneity was observed among studies which 
were pooled for a per-lesion analysis ofHGD characterization with an f of86.2%. 
However, there was no heterogeneity among studies which were pooled together 
for a per-patient analysis (f=O%). We used meta-regression and subgroup analysis 
to identify the source of heterogeneity. The following subgroups were analysed 
separately; single centre or multicentre study, number of endoscopists <2 or ~ 2 , ,
number of patients <50 or ~ ~ 50, number of lesions examined <200 or ~ ~ 200, 
Quality of studies «12 or ~ ~ 12 scores on QUADAS) and whether 
autofluorescence imaging (AFI) is used along with NBI. The number oflesions 
was the only significant variable identified as to the cause of heterogeneity 
(P=0.005, relative DOR 88.52 [95% CI-l 0.04-781.36]) (table 3). When those 
studies with ~ 2 0 0 0 lesions 76, 188, 195 were pooled together, the sensitivity and 
specificity was 0.97 (95% CI 0.91-0.99) and 0.99 (95% CI 0.98-0.99). The DOR 
was 2566.8 (95% CI 741.38-8886.5) with an f of 0% (decreased from 86% when 
all 6 studies included). 
Studies used in SIM analysis: The studies used for analysis of SIM 
characterisation on per-patient basis showed good homogeneity (12=0%), however, 
when studies were pooled on per-lesion basis there was significant heterogeneity 
(e=94.7%). The subgroup analysis showed that the number ofSIM lesions 
examined « I 00 or ~ ~ 100) was the only significant variable responsible for the 
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Table 3: Meta-regression analysis to identify sources of heterogeneity 
HGO-per-lesion analysis SIM-per-lesion analysis 
Variables P Relative OOR (95% CI) P Relative OOR(95% CI) 
Number of endoscopists <2 0.33 0.04 (0.0-136.21) 0.59 3.31 (0.0 1-920.28) 
o r ~ 2 2
Number of patients <50 or 0.77 2.70 (0.0-21604.19) 0.84 1.86 (0.0-6065.47) 
~ 5 0 0
Number oflesions ( for 0.005 88.57 (10.04-781.36) 0.001 34.23 (11.92-98.30) 
HGO analysis <200 or 2:200 
lesions, for SIM < 100 or 
~ 1 0 0 0 SIM lesions evaluated) 
Quality of studies <12 or 0.412 4.68 (0.03-821.54) 0.99 0.97 (0.0-323.66) 
~ 1 2 2 on QUAOAS 
DOR- Diagnostic odds ratio, CI- Confidence interval 
heterogeneity (P=O.OOI, ROOR 34.23 [95% CI 11.92-98.30]) (table 3). When we 
pooled the studies with> 100 SIM lesions, the sensitivity and specificity was 0.99 
(95% CI 0.97-0.99) and 0.7 (95% CI 0.65-0.74). The DOR was 158.63 (95% CI 
62.54-402.33) with an e of 47% (decreased from 97% when a116 studies 
included). 
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4.5 Discussion 
4.5.1 Principal findings 
Narrow Band Imaging offers the advantages of chromoscopy without the need for 
any additional dye spray and is easy to use. However to obtain clear mucosal 
views in order to assess the pit patterns and microvasculature, magnification is 
necessary. In this meta-analysis we reported pooled analysis on a per-lesion and 
per-patient basis, as it is important to see whether NBI-Z analysis is beneficial 
from a patient perspective as well, rather than just in diagnosing lesions. Results 
suggest that NBI with magnification has a high diagnostic accuracy in 
characterising HGD both on per-lesion and per-patient analysis with sensitivity 
and specificity over 90%. The sensitivity ofNBI-Z in differentiating SIM is high 
but the specificity is poor. 
4.5.2. Clinical implications 
The high diagnostic accuracy ofNBI-Z for characterising HGD suggests that it is 
useful in accurately targeting biopsies and therapy of early neoplasia. This will 
reduce the need of multiple random biopsies and increase the yield of dysplasia. 
Also, in patients referred for endoscopic resection of early neoplastic lesions, NBI-
Z will help delineating the lesion and assist in determining the margins of 
endoscopic resection. On the other hand, patients with BO who are on 
surveillance, endoscopic resection for abnormal dysplastic areas detected by NBI-
Z will be useful for accurate local staging and as a curative therapy, without 
waiting for biopsy results and avoiding multiple endoscopies. In suspected or 
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small BO, NBI-Z could be useful in identifying SIM and targeting biopsies, even 
though the diagnostic accuracy is comparatively low. The pooled sensitivity is 
95%, but the specificity (65%) needs to be improved. One of the reasons for this 
could be the various novel classification systems used by observers including 
linear, ridged, villous and absent patterns as a marker of SIM. Once diagnostic 
patterns are standardised, the diagnostic accuracy could improve. For HGD, 
irregular micro-structural and vascular patterns have been accepted as the standard 
diagnostic patterns and consequently the diagnostic accuracy is high. 
4.5.3 Study limitations 
Like most meta-analysis of diagnostic accuracy, this study has a few limitations. 
We have not compared the diagnostic accuracy ofNBI-Z against white light 
(WLE), white light with zoom (WLE-Z) or chromoendoscopy as there is a paucity 
of data in the literature on this. Further comparative studies are necessary in order 
to advocate NBI-Z over other modalities. 
In order to include all relevant articles and reduce the effect of potential 
publication bias, we reviewed a range of electronic databases. We also included 
studies in all languages and hand searched references from the published studies. 
Assessment of publication bias is challenging in meta-analysis of diagnostic 
accuracy as the accuracy is assessed against reference standard and as such the 
outcome is not compared between two tests. In this context funnel plots are not 
useful. Smaller number of primary studies available for this meta-analysis also 
makes it difficult to interpret funnel plots 201. Incorporation bias is unlikely as 
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most studies indicate that histopathological interpretation is done without 
knowledge of the NBI findings. Verification bias is excluded as all lesions/patients 
included have index (NBI) and reference (histology) test. 
Heterogeneity was observed among studies, which is usual with meta-analysis of 
diagnostic accuracies. We performed meta-regression and sub-group analysis to 
identify the sources of heterogeneity. The number of lesions examined was the 
only variable which showed significance in the meta-regression and the 
consistency improved when studies with larger numbers of lesions were pooled 
together. Several slightly varied classification systems were used for the 
characterisation ofSIM in each of the studies, which also would add to the 
heterogeneity. 
Narrow band imaging itself has disadvantages. It needs a video processor and 
additional light source which will increase the cost of the procedure. Moreover, a 
detailed examination of mucosa to differentiate various micro-structural and 
vascular patterns needs a magnification scope, adding to the capital cost. Presence 
of blood on the mucosa will make characterisation by NBI very difficult and hence 
operators have to be careful to avoid suction trauma to the lesions. Also, once 
biopsies are done, it becomes difficult to examine the rest of the dysplastic area. 
Inflammation with increased vascularity can be misinterpreted for dysplasia, based 
on the vascular characteristics. The studies in this meta-analysis used the older 
generation GIF Q240Z endoscope. Currently high definition and higher resolution 
endoscopes are available and further studies looking at the additive value of these 
endoscopes are needed. 
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4.5.4 Conclusions 
NBI-Z has a high diagnostic precision in lesion characterisation of high grade 
dysplasia in BO. NBI-Z will help target endoscopic biopsies and in delineating 
resection margins during endotherapy of dysplastic areas. Use ofNBI in lesion 
characterisation for specialised intestinal metaplasia seems to be less accurate, 
probably due to the different classification of micro-structural patterns used, but 
could be improved with adoption of standardised classification systems. 
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Author Mean Age No. Of Total No. Of Study design Endoscope Index test Reference Number of QUADAS 
(year) (Y)I subjects lesions type (NBI standard endoscopists score 
Males (%) examined classification) (histology) 
Kara et.al 2006 65/50(79%) 63 198 Cross GIF Q240Z Mucosal High grade 2 10/14 
(194) sectional, pattern, dysplasia, 
Post hoc Vascular specialised 
Image pattern intestinal 
evaluation metaplasia 
Kara et.al 2006 66/17(85%) 20 47 Cross GIF Q240Z Mucosal High grade 2 13/14 
(84) sectional, real pattern, dysplasia 
time Vascular 
evaluation pattern 
Sharma et.al 64/50(98%) 51 204 Cross GIF Q240Z Mucosal High grade Not stated 12/14 
2007 (195) sectional, pattern, dysplasia, 
image Vascular Specialised 
evaluation pattern intestinal 
metaplasia 
CurveTS et.al 67170(83%) 84 165 Cross GIF Q240Z Mucosal High grade 5 13/14 
2008 (86) sectional, real pattern, dysplasia 
time Vascular 
evaluation pattern 
Singh et.al 61.9177(71%) 109 1021 Cross GIF Q240Z Mucosal High grade 4 12/14 
2008(76) sectional, post pattern, dysplasia, 
hoc image vascular specialised 
evaluation pattern intestinal 
metaplasia 
Goda et.aI2007 60/51(88%) 58 217 Cross GIFQ240Z Mucosal Cancer, 1 12/14 
(196) sectional, real pattern, Specialised 
time Vascular intestinal 
evaluation pattern metaplasia 
Anagnostopoulos 62.l/34( 68%) 50 344 Cross GIFQ240Z Mucosal High grade 3 11114 
et.al2007 (188) sectional, pattern, dysplasia. 
realtime Vascular Specialised 
evaluation pattern intestinal 
metaplasia 
Hamamoto et.al 61.2/6(55%) 11 35 Case series, GIFQ240Z Mucosal Specialised 1 4/14 
2004(197) Post hoc pattern, intestinal 
image Vascular metaplasia 
evaluation pattern 
-- ---- - - - - -
Table 2: Characteristics of studies included in the meta-analysis 
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CHAPTERS 
ROLE OF VIDEO AUTOFLUORESCENCE 
ENDOSCOPY IN DETECTION OF DYSPLASIA IN 
BARRETT'S OESOPHAGUS; A META-ANALYSIS 
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5.1 Abstract 
Background and aims 
Autofluorescence imaging (AFI) is a novel technique which highlights abnormal 
or dysplastic areas in Barrett's oesophagus and is used as a 'red flag' technique. 
Various published studies have shown conflicting results regarding the accuracy 
of this technique. The aim of this study was to compare the diagnostic yield of 
Barrett's dysplasia between AFI and white light endoscopy (WLE). 
Method 
A meta-analysis of all prospective studies which compared lesions detected by 
AFI with histopathology as the gold standard was performed. Electronic databases 
were searched with key words "Autofluorescence and Barrett's". Forest plots 
were formulated to display estimates of accuracy. The pooled incremental yield 
for dysplasia detection of AFI over WLE was calculated. 
Results 
An initial search provided 54 studies and 5 studies met our inclusion criteria. 350 
patients with 521 AFI detected lesions were included in the final analysis. The 
incremental yield for detecting high grade dysplasia/cancer by AFI over WLE was 
49% (95% CI 42%-56%). For detection of all dysplasia, the incremental yield was 
46% favouring AFI (95% CI 25%-67%) when 3 studies with available data were 
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included. The event rates for false positive detection oflesions were 75% (95% CI 
58%-86%) for AFI and 70% for WLE (95% CI 54%-82%). White light endoscopy 
is more likely to miss HGD/cancer (OR 3.58,95% CI 1.8-7) and all dysplasia (OR 
4.26, 95% CI 0.88-20.7) compared to AFI. 
Conclusion: Autofluorescence imaging is more likely to detect high grade 
dysplasia/cancer and all dysplasia compared to white light endoscopy in Barrett's 
surveillance. This is at the expense of significant false positive lesion detection. 
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5.2 Introduction 
Regular surveillance in Barrett's oesophagus is perfonned with a view to identify 
early dysplastic lesions which could be treated at an early stage 202,203. This is 
likely to improve clinical outcome for patients compared to those presenting with 
symptomatic cancers. The routine practice in EO surveillance is to observe for any 
early lesions, which could then be target biopsied. In the absence of any obvious 
lesions, random four quadrant biopsies are taken every 2 cm as recommended by 
various national Gastroenterology societies 126,204. The random biopsy technique 
is associated with significant sampling error. Image enhanced endoscopy 
techniques as well as chromoendoscopy were used with a view to improve the 
detection of subtle early lesions with variable results. 
Autotluorescence video endoscopic imaging is a relatively new technique which 
was introduced in 2005 83. This endoscope is equipped with two CCD, one for the 
white light imaging and the other for AF imaging. The basis of this technique 
involves the fact that, when certain endogenous tluorophores in the 
gastrointestinal tract is excited with light of short wavelength, they emit light of 
long wavelength. This is captured after filtering the short wavelength light to 
incorporate into a pseudo colour image. The nonnal mucosa appears green related 
to the absorption spectrum of haemoglobin and the abnonnal or dysplastic tissue 
will have reduced tluorescence seen in magenta/purple colour. 
The AF imaging was studied predominantly in enriched Barrett's population and 
the results were suggestive of high sensitivity in picking up early dysplastic 
lesions. However, this is associated with a high false positive rate and hence low 
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specificity. This meta-analysis was aimed to assess the incremental yield of 
detecting dysplastic lesions by AFI compared to white light endoscopy (WLE). 
5.3 Methods 
5.3.1 Search strategy 
Literature search was done in various databases including Medline, Google 
Scholar, Web of Science and Cochrane databases. The search terms used were 
'Autofluorescence and Barrett's'. Articles in all languages were searched. We also 
hand-searched references from published articles. Abstracts were not included. 
5.3.2 Selection of studies 
All studies reporting the accuracy of AF imaging and WLE in Barrett's 
oesophagus with histology as gold standard were included. The inclusion criteria 
were a) prospective evaluation of autofluorescence imaging in BO, b) histological 
confirmation of the abnormal lesions c) real time assessment of lesions or post-hoc 
analysis and d) video autofluorescence endoscopic system is used. 
Studies without histological confirmation and those without extractable data were 
excluded. Also, case reports, case series, editorials, inter-observer studies, 
commentaries and data reported as abstracts only were excluded. Moreover, 
studies which used light induced fluorescence endoscopy (LIFE) and laser induced 
spectroscopy systems were excluded. Data from studies were independently 
extracted by two investigators and any discrepancies were resolved by discussion. 
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5.3.3 Meta-analysis 
A meta-analysis was performed with the following outcomes; the yield of AFI and 
WLE in detecting HGO/cancer and all dysplasia. Furthermore, the event rates for 
false positive detection of lesions were calculated for AFI and WLE. FinaJly, the 
miss rates ofHGD/cancer and all dysplasia by AFI and WLE were analysed. The 
incremental yield of AFI was calculated by subtracting the yield of WLE from that 
of AFI and a 95% confidence interval was calculated. A fixed effects model was 
used unless there was significant heterogeneity, in which case the DerSimonian-
Laird random effects model was used 205. Comprehensive Meta Analysis version 
2.2 (Biostat, Englewood, New Jersey, USA) statistical package was used for the 
data analysis. 
5.3.4 Heterogeneity analysis 
The Cochran's Q was used to test heterogeneity among the pooled estimates. 
Statistical heterogeneity was also assessed using 12 (inconsistency) that quantifies 
the proportion of inconsistency in individual studies that cannot be explained by 
chance. Values ofe such as 25%, 50% and 75% represent inconsistency which is 
low, moderate or high respectively. To test publication bias, a test for asymmetry 
of the funnel plots as suggested by Egger et at was used 206. 
5.4 Results 
A Pubmed search revealed 54 potentially relevant articles. 49 articles were 
excluded by reading the abstracts and/or the full text articles. These included 
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reviews, commentaries, case reports, correspondence and inter-observer studies. 
Articles pertaining to the light induced fluorescence (LIFE), laser fluoroscopy and 
spectroscopy were also excluded and finally 5 papers which used the video 
autofluorescence endoscopy and have extractable data were included in the 
analysis 83,84,86,171,207. No additional articles were retrieved from other sources. 
A115 studies provided data on the detection of lesions containing HGD/early 
cancer. Only 3 studies provided data on all dysplastic lesions detected by these 
modalities 83,171,207. All 5 studies had sufficient data to analyse the false positive 
rates (FPR) of AFI and 4 studies provided the information on FPR of WLE 84,86, 
171,207. The miss rates for HGD/cancer were calculated from 4 studies 83,86,171,207 
and that of all dysplasia were calculated from 3 studies which provided sufficient 
data 83,171,207. 
5.4.1 Detection of high grade dysplasia/cancer 
Five studies with 350 patients and 521 lesions were included in the analysis. The 
pooled incremental yield of AFI over WLE for detecting HGD/cancer was 49% 
(95% CI 42%-56%). Figure 1 shows the Forest plot for the incremental yield of 
AFI over WLE in the selected studies. 
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study name 
K8f"a 2005 
K8f"a 2006 
Curven2008 
Curvers 2010 
Curven2011 
statistics for each study 
Risk Lower Upper 
difference limit limit p-V.lue 
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Figure 1: Pooled incremental yield of AFI compared to WLE in detecting 
IIGD/cancer 
Funnel Plot of Standard Error by Risk difference 000, 
.. 
o 
.. 
.. 
0.05 
wO.10 
"U 
.. 
• 
"U 
C 
• 
U)0.15 
0.20 
·2.0 ·1.5 
I 
<> 
·1.0 ·0.5 0.0 0.5 1.0 1.5 
Rlak dlfferenoe 
2.0 
Figure 2: Funnel plot for publication bias for detection of IIGD/cancer 
comparing AFI and WLE 
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A fixed effect model was used for analysis as the heterogeneity was low 
(Cochran's Q 1.5, p=0.83, e=O%). Publication bias was excluded by a funnel plot 
(figure 2) and Egger's regression asymmetry test (p=0.4, intercept= -1.72,95% CI 
-7.36 to 3.91) 
5.4.2 Detection of all dysplasia 
3 studies with a total of 372 lesions were included in the analysis for all dysplastic 
lesions. The pooled incremental yield for AFI for detecting all dysplastic lesions 
compared to WLE was 46% (95% CI 25%-67%). Figure 3 shows the Forest plot 
for the incremental yield of AFI over WLE in the selected studies. A random 
effect model was used as the heterogeneity between the studies was high 
(Cochran's Q 15.69, P=<O.OOI, e 87%). Publication bias was excluded by Egger's 
regression symmetry (p=0.40, intercept= -6.50, 95% CI -67.1 to 54.1). 
5.4.3 False positive rates 
The pooled false positive rates (FPR) for each modality were calculated as event 
rate or the proportion of lesions which were false positive. All 5 studies were 
included in the analysis for AFI and 4 studies with available data were used for 
FPR of WLE. The pooled false positive rates for AFI in detecting dysplastic 
lesions was 75% (95% CI 58-86%) on a random effects model (figure 4). For 
WLE, the pooled FPR was 70% (95% CI 54-83%) (figure 5). Random effects 
model was used as heterogeneity among studies were high (AFI-Cochran's 
Q=48.9, e 92%, for WLE-Cochran's Q=15.7, e 81%). 
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Sludyname StaUsttcs for each study Risk dtrrerence and 95% CI 
Risk Lower Upper 
dil'ference limit limit p-Value 
Kara2005 0.500 0.343 0.657 0.000 
Curvers 2010 0.608 0.522 0.694 0.000 
Curvers 2011 0.256 0.106 0.408 0.001 
0.461 0.251 0.671 0.000 
-1.00 -(UiO 0.00 0.50 1.00 
Favours WLE Favours AFI 
Figure 3: Pooled incremental yield of AFI compared to WLE in detecting all 
dysplasia 
Study name Statistics for eaoh study 
Event Lower Upper 
rate limit limit p-Value 
Kara 2005 
Kara 2006 
0.506 0.399 0.613 0.912 
0.596 0.451 0.725 0.192 
Curvers 2008 0.814 0.126 0.818 
Curvers 2010 0.193 0.116 0.853 
Curvers 2011 0.891 0.839 0.936 
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Figure 4: Pooled false positive rates for autofluorescence imaging detected 
lesions 
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Studr name Statistics for each study Event rate and 95% CI 
Event Lower Upper 
rate limit limit p-Value 
Kera 2006 0.773 0.556 0.902 0.016 
--Curvers 2008 0.667 0.542 0.772 0.009 • Curvers 2010 0.529 0.411 0.644 0.628 
Curvers 2011 0.829 0.732 0.896 0.000 • 0.704 0.544 0.826 0.014 • 
-1.00 -0.50 0.00 0.50 1.00 
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Figure 5: Pooled false positive rates for white light endoscopy detected lesions 
Study name Statistics for each study Odds raUo and 95% CI 
Odds Lower Upper 
raUo limit limit p-Value 
Kera 2005 9.800 1.089 88.229 0.042 
Curvers 2008 7.815 1.958 31.615 0.004 • • 
Curvers 2010 3.063 1.088 8.619 0.034 -. 
Curvers 2011 1.316 0.306 5.649 0.112 
-
-3.571 1.802 1.099 0.000 • 
0.01 0.1 1 10 100 
AA .... eel ..... WLE .. ued ..... 
Figure 6: Pooled Odds ratio of miss rates of high grade dysplasia or cancer 
compared between AFI and WLE 
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Stud¥name Statistics '0,. each study Odds f"Btio and 95% CI 
Odds Lowe,. Uppe,. 
f"BOO limit limit p-Value 
Kara 2005 7.792 0.928 65.433 0.059 
Curvers 201010.375 3.461 31.102 0.000 
Curvers 2011 1.349 0.725 2.512 0.344 
4.259 0.875 20.725 0.073 
0.01 0.1 1 10 100 
AA ........... Wl£ ........... 
Figure 7: Pooled Odds ratio of miss rates of all dysplasia compared between 
AFI and \VLE 
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5.4.4 Miss rates of high grade dysplasia and all dysplasia 
The odds of missing a lesion was calculated with number of patients with HGD 
for the calculation ofHGD miss rates and the total number of patients for the miss 
rates of all dysplasia. The pooled Odds ratio of missing HGD or early cancer was 
3.57 (95% CI 1.8-7. I) with WLE missing more number of lesions compared to 
AFI (Figure 6). A fixed effects model was used as the heterogeneity of studies was 
low (Cochran's = 3.93 p=0.27, 12 24%). Similarly the OR for an dysplastic lesions 
were 4.26 (95% CI 0.87-20.73) favouring AFI on a random effects model (figure 
7). The heterogeneity among the 3 studies included in this analysis was high 
(Cochran's Q= 11.3, p=0.004, 12 82%). There was no evidence of publication bias 
on the Egger's regression asymmetry analysis (p=0.44, intercept= 1.50, 95% CI -
9.7 to 12.7). 
5.5 Discussion 
This study was aimed to evaluate the added benefits of autofluorescence 
endoscopy compared to white light endoscopy in terms of detection of lesions 
containing primarily high grade dysplasia and cancer. AFI is found to identify 
more number of dysplastic lesions during 80 surveillance compared to WLE, but 
high false positive rates were reported. This indicates that the more number of 
lesions identified are at the expense of over calling dysplasia during surveillance. 
This study showed that the incremental yield of AFI in detecting HGD/cancer was 
49% compared to WLE. The studies included in the analysis did not show 
significant heterogeneity or publication bias. It could be argued that, more time is 
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spent on the endoscopic procedure by switching between AFI and WLE and the 
careful examination itself would have contributed to the higher pick up of 
HGD/cancer. The other argument is whether the higher HGD pick up is related to 
more number of biopsies taken as there are significantly higher false positive 
lesions detected during AFI. However, in this study, the pooled FPR rates for AFI 
and WLE was not significantly different (75% Vs 70%). The pooled incremental 
yield for AFI in detecting all dysplasia was 46% (95% CI 25%-67%) compared to 
WLE. This analysis included only 3 papers with significant heterogeneity and 
hence the results should be viewed with caution. 
The pooled FPR for AFI was 75%. This has been a consistent finding in all the 
clinical studies. A study by Curvers et al attempted to identify predictive factors 
for true positive lesions detected during BO surveillance 208. The study suggested 
that opaque intensity, abnonnality in WLE and remoteness to gastric folds are 
potential factors predicating the true positive nature of the lesions. These factors 
should be considered during endoscopic examination which might help to reduce 
the false positive rates. 
White light endoscopy is more likely to miss HGD/cancer compared to AFI (OR 
3.6,95% CI 1.8-7.1). Similarly, the miss rates for WLE in detecting all dysplasia 
were 4.3 times higher than the AFI. This is particularly significant finding in an 
enriched Barrett's population, but whether this would be applicable in routine 
Barrett's surveillance is not clear. The use of white light endoscopy in studies was 
heterogeneous; some of the studies used high resolution endoscopy 83,84,86 and 
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other studies used standard definition endoscopy 171,207. However, all studies 
showed a higher detection of dysplasia by AFI. 
5.5.1 Limitations of the study 
As with any meta-analysis there are several potential limitations to this study 
especially by pooling data from different trials. The variations in the study 
designs, inclusion and exclusion criteria, operator experience and interpretation of 
findings could have all contributed to the heterogeneity. Some of the studies have 
included small number of patients and are potentially subject to selection bias. By 
pooling data from such studies, selection bias would be amplified. 
5.5.2 Conclusions 
Autofluorescence imaging is more likely to detect high grade dysplasia, cancer 
and all dysplasia in an enriched Barrett's population compared to white light 
endoscopy. The miss rates for dysplasia by white light endoscopy were 
significantly higher compared to autofluorescence imaging. However, the 
increased dysplasia detection rate of AFI was at the expense of high false positive 
lesion detection. The use of AFI could improve the overall yield of dysplasia, but 
could not replace random biopsy sampling. 
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CHAPTER 6 
AN INTER-OBSERVER AGREEMENT STUDY OF 
AUTOFLUORESCENCE ENDOSCOPY IN 
BARRETT'S OESOPHAGUS AMONG EXPERT AND 
NON-EXPERT ENDOSCOPISTS 
Mannath J, Subramanian V, Telakis E, Lau K, Ramappa V, Wireko M, Kaye PV, 
Ragunath K. Dig Dis Sci. 2013 Feb; 58(2):465-70 
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6.1 Abstract 
Background 
Autofluorescence imaging (AFI) is a 'red flag' technique during Barrett's 
surveillance to identify subtle abnormal lesions. AFI is associated with significant 
false positive results, but the reported sensitivity is high. The aim of this study was 
to assess the inter-observer agreement (lOA) in detecting AFI positive lesions and 
to assess the overall accuracy of AFI. 
Materials and methods 
Anonymised AFI and high resolution white light (HRE) images were 
prospectively collected. The AFI images were presented in random order, 
followed by corresponding AFI+HRE images in a second folder. Three AFI 
experts and 3 AFI non-experts scored images after a training presentation. The 
lOA was calculated using kappa and accuracy was calculated with histology as 
gold standard. 
Results 
74 sets of images were prospectively collected from 63 patients (48 males, mean 
age 69). The lOA for number of AF positive lesions was fair when AFI images 
were presented. This improved to moderate when corresponding AFI and HRE 
images were presented (experts 0.57 [0.44-0.70], non-experts 0.47 [0.35-0.62]). 
The lOA for the site of AF lesion was moderate for experts and fair for non-
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experts using AF images, which improved to substantial for experts (k 0.62 [0.50-
0.72]) but remained at fair for non-experts (k-0.28 [0.18-0.37]) with AFI+HRE. 
Among experts, the accuracy of detecting dysplasia was 0.76 (0.7-0.81) using AFI 
images and 0.85 (0.79-0.89) using AFI+HRE images. The accuracy was 0.69 
(0.62-0.74) with AFI images alone and 0.75 (0.70-0.80) using AFI+HRE among 
non-experts. 
Conclusion 
The lOA for AF positive lesions is fair to moderate using AFI images which 
improved with addition of liRE. The overall accuracy of identifying dysplasia was 
modcst which was bettcr when AFI and liRE images were combined. 
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6.2 Introduction: 
Regular endoscopic surveillance in Barrett's oesophagus (BO) is recommended to 
detect dysplastic changes or early cancer at a curable stage which in tum could 
. h . 126 209 Th d I . I . ft d'ffi I Improve t e prognosIs ' . ese ysp ashc eSlOns are 0 en I ICU t to 
identify with conventional endoscopy and various image enhanced techniques are 
now available. Autofluorescence imaging (AFI) endoscopy is a relatively new 
technique which utilises the endogenous fluorophores of the gastrointestinal tract. 
When a light of short wavelength interacts with these fluorophores, they emit light 
of longer wavelength. A composite pseudo colour image is formed by the 
processor of the endoscope using the emitted light 83 • Earlier studies in Barrett's 
eosophagus have shown that, AFI has a high sensitivity in diagnosing dysplastic 
areas in Barrett's oesophagus. The abnormal areas are seen in 'magenta' or 
'purple' colour compared to the normal tissue in 'green' colour depicting the 
absorption spcctrum of haemoglobin. However, the specificity of AFI was low 
with significant false positive rates in all the studies 86, I7I, 207, 2\0. The AFI is thus 
predominantly used as 'red flag' technique to highlight suspicious areas which 
could then be closely observed with liRE or NBI with magnification to look at the 
vascular and pit patterns 76, 199. There is limited data on what constitutes an 
abnormal area in the AFI as there are various factors which could cause false 
positive signals. Previous studies have shown that a 'purple' colour area away 
from gastro-oesophageal junction, which is opaque and ill defined, might suggest 
dysplasia 20M. AFI is an easy to use technique in regular surveillance of Barrett's 
and potentially can pick up flat and inconspicuous dysplasia. We aimed to assess 
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the inter-observer agreement in detecting AF positive lesions among AFI experts 
and AFI non-experts. We also aimed to assess the diagnostic accuracy of dysplasia 
using AFI images between these groups. 
6.3 1\fethods 
6.3.1 Patients 
Patients included in this study were those undergoing routine Barrett's 
surveillance and those referred to our centre for dysplasia work up and 
management. All patients were included in various single centre and mu]ticentre 
ethically approved Barrett's trials involving imaging and endotherapy. This study 
conforms to the ethiea] guidelines of the World Medica] Association Declaration 
ofllelsinki 211 and signed informed consent was obtained from all patients prior to 
the procedure. The endoscopic images were obtained by experienced endoscopists 
and were stored as high quality anonymised JPEG images in our central database. 
Corresponding biopsy specimens were taken from areas of interest which was 
imaged. 
6.3.2 Endoscopic equipment 
High resolution endoscopes G]F Q240 FZ and GIF Q260 FZ (O]ympus Keymed, 
UK) with a Olympus Lucera spectrum processor (Olympus Keymed, UK) 
equipped with a red. green and blue (RGB) sequential illumination xenon light 
source (XCL V -260IlP), RGB filters and a high definition television monitor 
(Olympus OEVI81 II) were used for the procedures. These endoscopes have an 
135 
additional autofluorescence chip at the tip. The operator could easily alternate 
between white light endoscopy and AFI by pressing a button on the hand control. 
When AFI is switched on, the mucosa is sequentially excited with blue light (390-
470 nm) and green light (540-560 nm). A barrier filter placed in front of the AFI 
CCD allows only passage of fluorescence light with a wavelength between 500 
and 630 nm after blue light excitation and of the green reflected light after green 
light excitation. The video processor subsequently constructs a pseudo colour 
image on the basis of the total AF and green reflectance 208. 
6.3.3 Endoscopic procedure 
All endoscopies were done under topical anaesthesia with 2% lignocaine spray or 
sedation using midazolam or diazepam with or without pethidine. During 
endoscopy, any suspicious areas are noted and separately sampled after capturing 
high quality liRE and AFI images (using a Sony BZMD-I DICOM Capture 
station or Sony liD Video GV-HD700E). Non-suspicious areas in BO are also 
imaged prior to random sampling. These images are stored as JPEG files (300 kb, 
1280 X 1024 pixel array and 32-bitcolour). All images were then anonymised and 
added to a database with corresponding lIRE and AFI images of each area. 
6.3.4 Selection of images for the study 
The images for this study were selected from the database (total of 44 7 images, 
IIRE=211, AFI= 236,) by a single endoscopist based on image quality, number of 
lesions, availability of corresponding set of AFI and HRE images for the same 
area and histological diagnosis. Images showing large lesions and obvious 
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cancers were excluded from the study. These images were imported into a training 
power point presentation (Microsoft Power Point 2007, Redmond, W A) and two 
separate folders containing AFI images alone and corresponding AFI and HRE 
images were inserted into Microsoft power point in a random fashion. All images 
were anonymised, presented without any changes to the original images and were 
of the same size and resolution. 
6.3.5 Image evaluation 
Three endoscopists experienced in advanced imaging (KR, VS, and ET) each of 
whom had done more than 200 advanced imaging procedures using AFI (AFI 
experts) and 3 experienced endoscopists (MW, KL, and VR) with no prior 
experience of AFI (AFI non-experts) but with significant experience in Barrett's 
surveillance using liRE (> 150 procedures) took part in the assessment of the 
anonymised images. Before starting the image evaluation a short automated 
power point presentation was provided to each endoscopist showing images of 
non-dysplastic Barrett's oesophagus, false positive AFI areas (non-dysplastic) and 
true positive AFI areas (dysplastic), in both HRE and AFI modes. 
After the training, all endoscopists independently assessed all images (74 AFI and 
74 corresponding AFI and liRE) presented in a random order. The endoscopists 
were instructed to record the findings a priori including a) presence of any 
abnonnal AFI signal (positive), b) site ofabnonnal AFI signal, c) whether 
dysplastic or not, and d) Quality of images on a visual analogue scale of 1-10. 
Finally the lIRE and AFI images from corresponding regions were displayed as 
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pairs and similar questions were repeated. Endoscopists were asked to answer 
these questions based on AFI images alone and were not asked to rate HRE 
images. All data were inserted into a separate Microsoft excel file by each 
endoscopist, which were analysed. The endoscopists were blinded to the 
histological diagnosis of these patients. 
6.3.6 Histological assessment 
Targeted biopsies were taken from abnormal areas as seen in AFI or HRE and in 
cases where there were no obvious mucosal abnormalities; random four quadrant 
biopsies were taken every 2 cm from the entire Barrett's mucosa. Random 
biopsies were also taken even if there were abnormal areas targeted. The 
specimens are fixed in 10% formalin and sent for histopathological assessment. 
The specimens were assessed by a specialist gastrointestinal pathologist (PVK) 
and in cases of dysplasia, by two different gastro-intestinal pathologists. The 
histopathological reporting was done according to Vienna classification 173. 
6.3.7 Statistical analysis 
The inter-observer agreement was expressed by the percentage of overall 
agreement among all observers, AFI experts and AFI non-experts as well as by an 
overall kappa (K) statistic with 95% confidence interval 212. The interpretation of 
K-valucs was done according to the values provided by Landis and Koch who 
characterised values < 0 as indicating no agreement and O-D.20 as slight, 0.21-
0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as substantial, and 0.81-1 as almost 
perfect agreement 213. Bootstrapping techniques (k=2000 bootstrap samples) was 
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used to obtain a bias corrected confidence intervals 214. On account of the 
correlated nature of the data we used bootstrapping techniques (k=2000 bootstrap 
samples) to obtain P values for differences in lC-values between experts and non-
experts. Stata version 9 (Stata Corporation, College Station, Texas) and PASW® 
version 17 (SPSS Inc, Chicago, Illinois) were used for the analysis. Continuous 
outcomes variables are given as mean ± standard deviation and were analysed 
using the t test. P < 0.05 was considered statistically significant. Sensitivity, 
specificity and accuracy were calculated with histopathology as gold standard. For 
analytical purposes LGD was grouped with non dysplastic Barrett's and 
HGD/IMC was analysed as dysplastic Barrett's. 
6.4 Results 
74 scts of anonymised images of AFI and HRE were collected from 63 patients 
(males 48, mean age 69). The histopathological diagnosis in these 74 sets were; 
Intramucosal cancer (lMC) =16, High grade dysplasia (HGD) =16, Low grade 
dysplasia (LGD) = 11. and Non-dysplastic Barrett's (NDBO) =31. 
6.4.1 Number of AF positive lesions 
The inter-observer agreement (lOA) (kappa) for number of true AFI positive 
lesions when only AFI images were shown was fair for all observers, experts and 
non-experts which improved to moderate when both AFI and HRE images were 
shown. Percentage of full agreement is shown in Table 1. 
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Table 1: Inter-observer agreement K (95% CI) for the number of AF positive 
lesions 
Full 
AFI agreement AFI+ HRE Full P value 
K(95% CI) AFI (%) K(95% el) agreement 
AFI+HRE 
(%) 
All observers 0.301 (0.235- 16 0.484 (0.401- 38 0.002 
0.384) 0.584) 
Experts 0.392 (0.272- 46 0.567 (0.443- 65 0.044 
0.518) 0.700) 
Non-experts 0.259 (0.142- 36.5 0.473 (0.347- 61 0.02 
0.381) 0.615) 
P value 0.08 0.32 
AFI-Autotluorcscence Imagmg, HRE-Il!gh resolution imaging, k-Kappa 
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6.4.2 Site of AF positive lesions 
The kappa for all observers for the site of AF positive lesion was 0.392 (95% CI 
0.316-0.474) with AFI images alone which improved to 0.435 (95% CI 0.358-
0.518) with corresponding AFI + HRE images. Among experts, the kappa for site 
of AF positive lesion was moderate which was significantly higher than non-
experts (P=O.O 1) when AFI images were presented. When corresponding AFI + 
HRE images were shown, kappa for experts improved to substantial (k = 0.615 
[95% CI 0.498-0.721 D, but remained at fair for non-experts (k= 0.275[95% CI 
0.182-0.377]). Percentage of full agreement is shown in Table 2. 
6.4.3 Inter-observer agreement for dysplasia 
The lOA for presence of high grade dysplasia or early cancer was moderate (k = 
0.410 [95% CI 0.300-0.527]) for all observers with AFI images which improved 
to substantial (k= 0.614 [95% CI 0.509-0.717]) with corresponding AF and white 
light images. Among experts, the kappa with AFI images alone was 0.492 
(moderate, 95% CI 0.339-0.654) and 0.781 (substantial, 95% CI 0.646-0.874) with 
combined AFI + HRE images. Among non-experts, the kappa with AFI images 
alone was 0.381 (95% CI 0.225-0.551) and 0.478 (95% CI 0.333-0.627) with AFI 
+ HRE images. Percentage of full agreement is shown in Table 3. 
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Table 2: Inter-observer agreement K (95% CI) for the site of AF positive 
lesions 
Full 
AFI agreement AFI+HRE Full P Value 
K(95% CI) AFI (%) K(95% el) agreement 
AFI+HRE 
(%) 
All observers 0.392 (0.316- 15 0.435 (0.358- 15 0.45 
0.474) 0.518) 
Experts 0.478 (0.372- 45 0.615 (0.498- 62 0.09 
0.595) 0.721) 
Non-experts 0.276 (0.167- 24 0.275 (0.182- 20 0.98 
0.384) 0.377) 
P value 0.01 <0.001 
AF1-Autofluorescence imagmg, lIRE-High resolutIOn endoscopy, K-Kappa 
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Table 3: Inter-observer agreement K (95% CI) for dysplasia 
Full 
AFI agreement AFI+HRE Full P value 
K(95% CI) AFI (%,) K(95% el) agreement 
AFI+HRE 
(%) 
All observers 0.410 (0.300- 38 0.614 (0.509- 57 0.01 
0.527) 0.717) 
Experts 0.492 (0.339- 62 0.781 (0.646- 84 0.004 
0.654) 0.874) 
Non-experts 0.381 (0.225- 57 0.478 (0.333- 64 0.38 
0.551) 0.627) 
P value 0.33 0.001 
AFI-Autofluorescence imagmg, HRE-Hlgh resolution endoscopy, k-kappa 
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Table 4: Sensitivity, specificity and accuracy (95% el) of dysplasia with 
histology as gold standard 
Experts Non-experts All observers 
AFI AFI+ AFI AFI+ AFI AFI+ 
lIRE lIRE lIRE 
Sensitivity 0.75 (0.68 0.84 (0.78- 0.56 (0.49- 0.64 (0.57 0.66 (0.6- 0.74 (0.69-
- 0.8]) 0.89) 0.62) - 0.69) 0.7) 0.78) 
Specificity 0.76 (0.7] 0.85 (0.80- 0.78 (0.72- 0.83 (0.78 0.77 (0.73- 0.84 (0.81-
- 0.8]) 0.89) 0.83) - 0.88) 0.8) 0.87) 
Accuracy 0.76 (0.70 0.85 (0.79- 0.69 (0.62- 0.75 (0.70 0.72 (0.68- 0.8 (0.76-
- 0.8]) 0.89) 0.74) - 0.80) 0.76) 0.83) 
AFI-Autofluorcsccnce Imagmg, liRE-HIgh resolution endoscopy 
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6.4.4 Accuracy of dysplasia detection 
Using histopathology as gold standard the sensitivity and specificity for dysplasia 
detection was calculated. Among experts, the sensitivity and specificity was 0.75 
(95% CI 0.68-0.81) and 0.76 (95% CI 0.71-0.81) when AFI images were used 
alone. When both AFI and liRE images were shown together, the sensitivity and 
specificity improved to 0.84 (95% CI 0.78-0.89) and 0.85 (95% CI 0.80-0.89). 
Among non-experts the sensitivity and specificity were 0.56 (95% CI 0.49-0.62) 
and 0.78 (95% CI 0.72-0.83) with AFI images alone. The sensitivity and 
specificity were 0.64 (95% CI 0.57-0.69) and 0.83 (0.78-0.88) when AFI + HE 
images were presented among non-experts. The overall accuracy is shown in 
Table 4. 
6.4.5 Quality of AFI images 
The overall quality of AFI images on a visual analogue score of 1-10 (l=Poor, 
10=Best) were 6.27 ± 1.64 (mean ± SD) for all observers when AFI images were 
presented on its own. For experts, the mean VAS score was 6.44 ± 1.53 and for 
non-experts it was 6.1 ± 1.73. When AFI + HRE images were shown the mean (± 
SD) V AS scores for AFI images for all observers, experts and non-experts were 
6.83 ± 1.62, 6.65 ± 1.3, 7 ± 1.87 respectively. 
6.5 Discussion 
This study has directly assessed the inter-observer agreement of AFI positive 
lesions in patients with 80 and has ascertained the accuracy of detection of high 
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grade dysplasia and early cancer with histology as gold standard. This image 
enhanced technique is user friendly and is used as a 'red flag' technique during 
BO surveillance. It is important to assess the IDA among experts and non-experts 
in identifying such abnormal areas to understand the value of this technique in 
routine clinical practice. The predictive factors for dysplasia in AFI were studied 
earlier and the investigators found that abnormal AF signals (magenta or purple) 
with opaque AF intensity and mucosal abnormalities in HRE images are highly 
suggestive of dysplasia. They also found that abnormal AF signals in proximity to 
gastric folds are likely to be false positive 208. We included these three criteria in 
the training session along with presenting other common false positive signals in 
the context of scarring, inflammation and squamous mucosal islands to prevent 
reporting false positive areas. 
The consistcnt finding is the improvement in lOA and dysplasia detection by 
experts and non-experts when combined AFI and HRE images were shown. This 
finding is in agreement with the previously discussed study 208. The clinical 
importance is that, switching between AFI and HRE is essential in real time 
endoscopy. However, the likelihood of dysplasia in the presence of an abnormal 
AFI signal and normal liRE findings needs to be ascertained in prospective 
studies. Also, the value of AFI imaging in itself as a tool for BO surveillance is 
questionable and should be combined with HRE. It is very easy for the operator to 
switch back and forth bctween AFI and liRE and the suspicious areas should be 
carefully examined by both modalities. 
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The non-experts demonstrated a low agreement on the number of AF positive 
signals and the site of AF positive areas compared to experts. This indirectly 
indicates a learning curve. A previous study indicated that NBI in differentiation 
of colonic polyps could be learned in 20 minutes by didactic lecturing 215. In our 
study, a power point presentation for 15 minutes does not seem to be sufficient to 
improve the IDA and accuracy of AFI in dysplasia detection. This needs to be 
clarified in prospective study with definitive aim directed towards it. 
The AFI non-experts have significant experience in Barrett's surveillance using 
HRE only. This might explain the statistically significant improvement in the IDA 
of number of AF positive lesions when both AFI and HRE images were shown 
compared to AF images alone. Nonetheless, there was no significant improvement 
in the IDA of site of AF positive lesions or dysplasia with combined images. This 
reflects the learning curve in identifying the areas of true positive AFI signals. 
This argument is strengthened by the fact that, AFI experts significantly improved 
lOA when liRE were added. 
There was no significant difference between experts and non-experts in the 
reported quality of AFI images and the VAS score was above average. This could 
be due to selection bias as only good images were selected for the study. The AFI 
experts however, scored the images similar to that of non-experts. 
The strength of this study is that 3 expert and 3 non-expert endoscopists 
participated in the study with a comparable number of dysplastic and non-
dysplastic Barrett's images. The overall accuracy of dysplasia among experts was 
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good at 0.76 with AFI images and 0.85 with AFI+HRE images. This indicates that 
the technique is valuable in correctly identifying dysplasia by experts. However, 
no comparison was done between HRE and AFI and thus results does not reflect 
that AFI is better than HRE in indentifying dysplasia. Nevertheless, the combined 
use of AFI and HRE seems to be of value in the context. 
The quality of images assessed by both experts and non-experts were between 
6.27-7.0 (mean) on a VAS scale of 1-10. Arguably, an improvement in quality of 
images could improve the lOA and possibly the identification of dysplasia. 
Further studies with improved quality of images are necessary to ascertain this. 
6.5.1 Limitations of the study 
As with many previous inter-observer studies, endoscopic images were used in 
this study. This docs not reflect routine clinical practice where real time images 
are displayed on high definition monitors. However, in real time, many 
endoscopists assess the abnormal areas by freezing the images and this was 
mimicked in our study. Video clips of the relevant areas would have been a better 
way of assessment. 
The sensitivity and specificity is assessed using targeted histology as gold 
standard. Random biopsies were taken if there were no abnormal areas to target. 
This does not reflect the true sensitivity and specificity of the modality as there is 
significant sampling error in Barrett's and occult dysplasia would have been 
overlooked. The other limitation of the study is that for analytical purposes we 
have included low grade dysplasia along with non-dysplastic Barrett's as there are 
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no definitive AFI abnormalities described in cases of LGD. This study was done 
in enriched population and thereby is not a true reflection of Barrett's surveillance. 
The images were selected from a database of images and only good quality of 
images was selected. Also, there is no time pressure on endoscopists to comment 
on images unlike in real time settings. 
Considering the facts that this study was done using selected images and not a real 
time study, focused on dysplasia identification rather than detection and the 
significant but modest accuracy of dysplasia, it would not be possible to 
recommend AFI for routine use in Barrett's surveillance 
6.5.2 Conclusions 
The inter-observer agreement for AF positive lesions is fair to moderate using AFI 
images which improved with addition ofHRE. The overall accuracy of dysplasia 
identification using AFI images was modest, but was better among experts and 
with combined AFI and lIRE images. Better understanding of what constitutes an 
AF positive signal and improvement in technology to increase the quality of 
images could enhance the value of this endoscopic technique in BO surveillance. 
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CHAPTER 7 
UTILITY OF AN AUTOFLUORESCENCE INDEX TO 
DETECT EARLY NEOPLASIA IN BARRETT'S 
OESOPHAGUS; A PILOT STUDY 
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7.1 Abstract 
Background 
Auto-fluorescence imaging (AFI) endoscopy is a novel imaging technique that can 
identify neoplastic tissue by highlighting differences in tissue fluorescence 
properties and detect early neoplasia not detectable by conventional white light 
endoscopy. Although it has a high sensitivity, it is associated with a high false 
positive rate up to 80% 
Aims 
To determinc ifautofluoresccnce indcx dcfined as the ratio of the intensity of red 
and grccn tonc bctwecn normal and abnormal AFI areas in patients with Barrett's 
ocsophagus (BO) can improve thc specificity and accuracy of AFI endoscopy. 
Methods 
Imagcs of paticnts with both AFI truc and false positive areas of BO were selected 
from a prospcctivcly collcctcd datasct using the Olympus Lucera-Hyperpro 
prototypc vidco cndoscopy systcm and GIF Q240FZ gastroscope. Biopsies from 
thcsc areas had been confirmed by an experienced GI pathologist. The intensity of 
thc red and green tone at thc abnormal and 2 separate normal areas were read 
blindcd using thc NIS Elemcnts AR 2.30 imaging software (Nikon instruments, 
Japan). Statistical analysis was done using SPSS version 16 (SPSS Inc, USA). 
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Results 
There were 82 images of AFI abnormalities. Of these 19 had high grade dysplasia 
(HGD), 18 had carcinoma (Ca), 38 had specialised intestinal metaplasia without 
dysplasia (SIM) and 7 were that of columnar epithelium without SIM. The area 
under the receiver operating curve (AUROC) for the auto-fluorescence index (AF 
index) was 0.881 (95% CI 0.81-0.95) and 0.91 (95% CI 0.84-0.97) when utilising 
the two different normal AFI areas respectively for calculating the index. The two 
separate readings made were highly correlated (Spearman's rho 0.82). Using an 
AF index cut off of 1.32 the sensitivities for readings I and 2 were 92% (95% CI 
82-99) and 95% (95% CI 85-99) respectively, specificities were 76% (95% CI 67-
80) and 62% (95% CI 54-65). 
Conclusions 
The AF index shows promise as a tool to improve the diagnostic capabilities of 
AFI endoscopy. Further prospective studies with real time determination of the 
ratio during video AFI endoscopy will serve to confirm its utility in clinical 
practice. 
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7.2 Background 
Oesophageal adenocarcinoma (OA) has the fastest rising incidence in the western 
world and Barrett's oesophagus is the only known precursor lesion. The incidence 
ofOA has increased 4-6 folds over the past 4 decades 216,217 • When diagnosed at 
an advanced stage, OA has a poor prognosis 218. Early detection ofJesions wiIJ 
facilitate endotherapy or surgery and improve the prognosis. Due to this reason 
regular surveillance of BO is recommended 219. In recent years, various advanced 
endoscopic imaging techniques have facilitated the assessment and early detection 
oflesions. Autofluorescence imaging (AFI) is a technique which can potentially 
differentiate dysplastic from non-dysplastic areas in BO. Normal and neoplastic 
tissues have different characteristics in AFI 78. The initial use of AFI was limited 
to autofluorescence spectroscopy and use of fibre optic endoscopes. However 
these modalities produced poor picture quality of white light imaging. The new 
generation of AFI endoscopes has two high resolution chips, one for the white 
light and one for the autofluorescence imaging. The non-dysplastic area of the BO 
appears 'green' and the dysplastic areas appear 'pink or magenta'. However most 
of the studies with the new system have reported a high false positive rates 
ranging from 40% to 80% 84.86. The additional use ofNBI has found to reduce this 
false positivity. 
We investigated to identify an autofluorescence index which could enable to 
differentiate the truly dysplastic areas from false positive areas in AFI images. 
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7.3 l\fethods 
7.3.1. Images 
AFI images from dysplastic and non dysplastic Barrett's, which were 
prospectively collected, were retrieved from existing database. All lesions were 
confinned by target biopsies as to whether they harbor dysplasia. The criteria for 
selecting the images were a) adequate AFI image quality for analysis, b) the 
lesions seen were correlated with white light images, c) target biopsies were 
reviewed by a gastrointestinal pathologist, and d) only images with non dysplastic 
BO or that with early neoplasia. 
7.3.2 Endoscopy system 
The autofluorescence endoscope (XGIF-240FZ, Olympus, Tokyo, Japan) has 2 
separate CCOs, one for WLE and one for AFI. The system uses sequential red-
green-blue illumination for WLE. While using the AFI system, the mucosa is 
sequentially excited with blue light (390-470 nm) and green light (540 nm-560 
nm). A blue light filter is placed in front of the AFI CCO to allow only passage of 
reflected fluorescence light with a wavelength between 500 and 630 nm after blue 
light excitation and of the green reflected light after green light excitation. The 
video processor (XCV-260 HP3P, Olympus) receives the reflected light and 
constructs a pseudo colour image on the basis of the total autofluorescence and 
green reflectance. The pseudo colour image is produced by allocating the AF 
signal to the green (G) channel and the reflected signal of green light to the red (R) 
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and blue (8) channels in a 1 to 0.5 ratio 220. Non dysplastic Barrett's epithelium 
appears green during AFI, whereas suspicious areas appear red or magenta. 
7.3.3 Image analysis 
Digital images of AFI positive areas were captured using a digital video cassette 
recorder (Sony Mini DV GV-DIOOe PAL; Sony Corp., Tokyo Japan) and were 
stored as JPEG files (200-300kb, 1280 x 1024 pixel array and 32 bit colour). 
Gamma corrected images were analysed using NIS Elements AR 2.30 imaging 
software (Nikon instruments, Japan). All analysis was done blinded to the 
histopathological diagnosis. The region of interest, which shows low intensity 
signal (red or magenta). was traced using the software. The intensity of the red 
tone and green tone were calculated at this area. Two normally appearing areas 
(green) away from the suspected area were also traced. The mean red tone 
intensity and green tone intensity of both these areas were also calculated. The 
ratio of red tone to green tone (AF ratio) in the abnormal area to that of normal 
areas was pragmatically considered as the autofluorescence index (AF index). 
Two different sets of values obtained using the abnormal area and two normal 
areas in this manner. 
7.3.4 Statistical analysis 
Diagnostic test statistics of sensitivity, specificity, and predictive values were 
calculated by using histopathology determination as the gold standard. Statistical 
analysis was done using SPSS version 16 (SPSS Inc, USA). The two separate 
readings of AF indices were correlated using Spearman's rank correlation 
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coefficient. Receiver operating curves (ROC) analysis was used to find optimal 
cut off values for assessing dysplastic areas. Area under the receiver operating 
characteristic curve (AUROC) was obtained plotting the sensitivity on the X axis 
and I-specificity on the Y axis for both sets of recordings. 
7.4 Results 
There were 82 images of AFI abnormalities which were selected as per the criteria 
taken from 49 patients with BO (40 males, median age 68 years (lQR 57-76».19 
images were from areas of high grade dysplasia (HOD), 18 from areas of cancer, 
38 from non dysplastic Barrett's with specialised intestinal metaplasia and 7 were 
that of columnar epithelium. The AF index was calculated using the AF positive 
area and 2 normal background areas. The results were plotted to obtain a ROC 
(figure 1). The area under the receiver operating curve (AUROC) for the auto-
fluorescence index was 0.881 (95% CI 0.81-0.95) and 0.91 (95% CI 0.84-0.97) 
when utilising the two different normal AFI areas respectively for calculating the 
index (table 1). The two separate readings made were highly correlated 
(Spearman's ratio 0.82). Using the ROC curve, optimal AFI index cut off of 1.32 
was derived, which represents a sensitivity of 86% and specificity of 88%. 
The AF index value of 1.32 was used to define the sensitivity and specificity of 
the 82 images with histology as gold standard. The sensitivities for readings 1 and 
2 were 92% (95% CI 82-99) and 95% (95% CI 85-99) respectively, specificities 
were 76% (95% CI 67-80) and 62% (95% CI 54-65) and likelihood ratio ofa 
positive test was 3.8 (95% CI 2.5-4.6) and 2.5 (95% CI 1.9-2.8). None of the 
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cancers and only 3 and 2 HGD's respectively were misclassified by the AFI index 
of 1.32. 
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Figure 1: ROC of two different sets of autofluorescence index ratios 
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Coordinates of the ROC Curve 
Test Result Variable: Autofluorescence index ratios 
Autofluorescence index ratio Sensitivity I - Speciticity 
-.8438 1.000 1.000 
.3815 .973 1.000 
.6120 .973 .978 
.7668 .973 .956 
.9664 .973 .933 
1.0218 .973 .911 
1.0364 .973 .889 
1.0461 .973 .867 
1.0474 .973 .844 
1.0514 .973 .822 
1.0567 .973 .800 
1.0613 .973 .778 
1.0676 .973 .756 
1.0799 .973 .733 
1.0892 .973 .711 
1.0937 .973 .689 
1.1025 .973 .667 
1.1138 .973 .644 
1.1284 .973 .622 
1.1451 .973 .600 
1.1554 .973 .578 
1.l619 .973 .556 
1.1791 .973 .533 
1.l931 .946 .533 
1.1946 .919 .533 
1.1957 .919 .511 
1.2155 .892 .511 
1.2366 .892 .489 
1.2397 .892 .467 
1.2411 .892 .444 
1.2477 .892 .422 
1.2542 .892 .400 
1.2622 .865 .400 
1.2801 .865 .378 
1.2921 .865 .356 
1.2957 .865 .333 
1.2989 .865 .311 
1.3007 .865 .289 
1.3038 .865 .267 
1.3119 .865 .244 
1.3280 .865 .222 
1.3466 .838 .222 
1.3566 .838 .200 
1.3687 .811 .200 
1.3798 .784 .200 
1.3810 .757 .200 
1.3853 .730 .200 
1.3933 .703 .200 
1.4068 .703 .178 
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Autofluorescence index ratio 
Sensitivity I - Specificity 
1.4191 .703 .156 
1.4376 .676 .156 
1.4550 .649 .156 
1.4624 .649 .133 
1.4696 .622 .133 
1.4739 .595 .133 
1.4773 .595 .11 I 
1.4990 .568 .11 I 
1.5422 .541 .111 
1.5653 .514 .111 
1.5809 .486 .111 
1.5978 .486 .089 
1.6077 .459 .089 
1.6206 .459 .067 
1.6347 .432 .067 
1.6565 .405 .067 
1.6827 .378 .067 
1.7133 .378 .044 
1.7334 .378 .022 
1.7368 .351 .022 
1.7795 .324 .022 
1.8377 .297 .022 
1.8655 .270 .022 
1.8775 .243 .022 
1.8790 .216 .022 
1.8976 .216 .000 
1.9286 .189 .000 
1.9692 .162 .000 
2.0069 .135 .000 
2.0439 .108 .000 
2.1091 .081 .000 
2.1803 .054 .000 
2.6582 .027 .000 
4.1038 .000 .000 
Table 1: Coordinates of the receh'er operating characteristic curve showing 
the sensith'ity and I-specificity for various autofluorescence index ratios of 
one set of recordings. 
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7.5 Discussion 
AFI exploits differences in fluorescence properties of normal and abnormal 
gastrointestinal mucosa and facilitates the detection of early pre-invasive cancer. 
Although AFI is highly sensitive, it is associated with a very high false positive 
rate which can lead to excessive biopsies, longer procedure time and greater costs. 
Clinical studies have shown that as high as 75% of lesions with abnormal 
fluorescence were false positive when correlated with histology 86, 171. In this study 
we have shown that an autofluorescence index might be of value in differentiating 
dysplastic areas from non dysplastic BO. The sensitivity, specificity, and 
predictive values were calculated for several autofluorescence index ratios and, by 
using the ROC, a value of 1.32 was chosen as the best value to separate dysplastic 
area from a non-dysplastic area. This will help in reducing the high false positive 
rates associated with a subjective examination of the autofluorescence. The current 
system of autofluorescence video endoscopy does not provide an in vivo 
measurement of AF index and we hypothesised that there is a biological 
plausibility of increase in the index with increasing dysplasia. Thus, a cut off 
index ratio would be helpful to differentiate between normal and dysplastic areas. 
Light induced fluoroscopy system (LIFE) was used in the past to differentiate 
adenomatous polyps from non-adenomatous polyps using an index. They found 
cut off value of2.3 for their index, which has a sensitivity and specificity 85% and 
81 % 221. However this system produced poor quality images and is outdated now 
by the video autofluorescence endoscopy system. In the fibre optic system it was 
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possible to do the measurements of the index in vivo, producing immediate results 
to take clinical decisions. 
This study has a few limitations. The images were retrieved from a pre collected 
database and only those with good quality were obtained. There is selection bias 
involved in this. Also, the images are from patients referred to a tertiary referral 
centre and do not represent the true Barrett's surveillance population, causing 
referral bias. Moreover the images are gamma corrected and pseudo colour 
images. The value of in vitro assessment using image analysis software might not 
represent a clinical scenario. Also, as a pilot study, we have used a dataset to 
derive a cut off value of autofluorescence index and used this value on the same 
dataset for validation. The assessment of such an index is incomplete without 
validating in a different dataset. Nonetheless, we have identified a method to 
improve the diagnostic specificity of this emerging technology which is used 
currently as a 'red flag' system than a diagnostic method by itself due to the high 
false positive results. More studies using images from a prospective cohort would 
provide a better understanding of the index, which in the future could be 
incorporated into the endoscopy system to enable better in vivo diagnostic 
accuracy. 
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CHAPTERS 
CORRELATION OF QUANTITATIVE MEASURES OF 
AUTOFLUORESCENCE FROM VIDEO 
A UTOFL UORESCENCE ENDOSCOPY WITH 
COLLAGEN AND ELASTIN AND CHANGES OVER 
WITH TIME IN A l\10USE MODEL OF COLON 
CANCER (APCM1N MICE) 
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8.1 Introduction 
The theory of autofluorescence is based on the presence of natural fluorophores in 
the gastrointestinal tract. When light of a specific wavelength is focussed on 
tissue, several interactions occur at the cell interface. The light (consisting of 
photons) could be either reflected at the cell surface or penetrate the tissue and get 
absorbed by chromophores. The main chromophore in tissue which absorbs the 
visible wavelength of light is haemoglobin. Absorption of light occurs both with 
oxygenated or deoxygenated forms of haemoglobin 77,222. The third outcome from 
the interaction of light and tissue is absorption of the light followed by light of a 
longer wavelength being emitted by the tissue: a phenomenon termed as 
autofluorescence. During white light endoscopy, reflection and absorption are the 
main interactions between light and tissue. During white light video endoscopy in 
patients with Barrett's oesophagus, the mucosa appears 'salmon' pink in colour as 
most of the red light is reflected, but on the other hand green and blue light are 
absorbed by chromophores in the tissue. 
Fluorophores are biological substances which emit longer wavelengths 
(fluorescent light) when excited by short wavelength light such as blue light. Some 
of the fluorophores which are thought to be responsible for tissue autofluorescence 
include collagen, aromatic amino acids, nicotinamide adenine nucleotide (NADH) 
and porphyrins 77. However, this phenomenon is poorly understood. The changes 
in fluorescent properties in normal, metaplastic and dysplastic tissue would vary 
due to the different types, concentrations and distribution of various fluorophores 
and chromophores. 
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The phenomenon of reduced autofluorescence in dysplastic Barrett's compared to 
non-dysplastic Barrett's was thought to be related to the changes in mucosal 
thickening. This would attenuate the strong fluorescence from collagen rich sub-
mucosa. An ex-vivo study on snap-frozen mucosal biopsies from patients with 
Barrett's oesophagus scanned with confocal fluorescence microscopy showed that 
both dysplastic and non-dysplastic epithelium showed predominantly green 
fluorescence. The main source of the fluorescence was from both cytoplasm and 
lamina propria 223. Contrary to this, clinical studies have shown reduced 
autofluorescence in dysplastic Barrett's compared to non-dysplastic Barrett's. 
There are various mechanisms proposed as to the cause for this 77; 
1. The nuclear-cytoplasmic ratio increases in dysplastic cells and nuclei have 
little or no autofluorescence properties compared to cytoplasm 
2. The dysplasia is associated with increased mucosal thickness which would 
prevent the light from penetrating into the submucosal layer where the 
abundant collagen is thought to have the highest fluorescence in 
gastrointestinal tract 
3. An increased concentration of tissue haemoglobin in the mucosal layer 
associated with dysplastic process attenuates the autofluorescence 
This study was aimed to understand the biological basis and role of collagen and 
elastin in the process of autofluorescence 
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8.2 l\1aterials and methods 
8.2.1 Endoscopic equipment 
The autofluorescence endoscope (GIF-240FZ, Olympus, Tokyo, Japan) has 2 
separate CCDs, one for WLE and one for AFI and the process of producing 
autofluorescence image is described in chapter 7 under materials and methods. 
The video processor (XCV-260 HP3P, Olympus) receives the reflected light and 
constructs a pseudo colour image on the basis of the total autofluorescence and 
green reflectance. 
8.2.2 Mouse colon cancer model (APCmin mouse) 
Formalinised colonic specimens from Apcmin mice were used for this study as 
there are currently no acceptable animal models for Barrett's neoplasia. Familial 
adenomatous polyposis is a rare condition associated with multiple gastrointestinal 
polyposis and nearly 100% risk of colorectal cancer in humans. This is caused by 
a germ line mutation in the adcnomatous polyposis coli (APC) gene 224. Min 
(multiple intestinal neoplasia) is a mutant allele of the murine Apc locus, which 
encodes a nonsense mutation at codon 850 225• These APCmin strain are highly 
susceptible to intestinal adenoma and cancer formation. It is reported that nearly 
100% of the APCmin heterozygotes who are fed with high fat diet would develop 
more than 30 adenomas and they die by 120 days 226. 
The APCmin mice used in the study were taken from a study approved by the 
Nottingham Research Ethics Committee on the effect of chemo preventive agents 
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on colonic cancer fonnation and were in the placebo ann of the study. As part of 
the ethically approved protocol these mice were sacrificed at 12, 18 and 24 weeks 
and their colons preserved in fonnalin for histopathological analysis. These 
specimens were used for imaging and histopathological studies. No additional 
mice were sacrificed or used for the purpose of this study. A total of30 mice 
colons of which 10 sacrificed at 12 weeks, 10 sacrificed at 18 weeks and another 
10 mice colons sacrificed at 24 weeks were used in the study. 
8.2.3 l\lice colonic imaging 
The mice colons were stored in labe11ed formalin containers with details of the 
time of sacrifice of the animals. The mice colons were imaged according to the 
age at sacrifice. 10 each of the colons from 12 weeks, 18 weeks and 24weeks were 
imaged. These colons were dissected along the length to open the mucosal layer 
and pinned down to the board exposing the mucosal layer prior to imaging. 
The images were obtained using a GIF 240 FZ gastroscope (Olympus medical, 
Keymed UK) connected to a Olympus Lucera Spectrum processor (Olympus 
Keymed, UK) with a rcd-green-blue sequential illumination xenon light (XCLV 
260JlP) and a high definition monitor (Olympus OEVI81H). All images were 
captured with a Sony HD video GV HD700E and stored as JPEG files (300 Kb, 
1280 X 1024 pixel arrays). The original files were used for further analysis 
without any modification to the resolution of the images. Corresponding white 
light and autofluorescence images wcre obtained. Only AFI images were used for 
further evaluation. 
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8.2.4 Image analysis using soft ware 
A freely downloadable software called ImageJ (Image processing and analysing in 
Java) version 4.3 (National Institute of Health (NIH), USA) was used to do 
analysis of the mice colonic autofluorescence images. This software is a public 
domain java image processing programme which was inspired from NIH image 
which was developed by research services branch (RS8). The colonic images 
were opened with ImageJ. They were cropped to include only the colonic part and 
excluded the mounting board and needle points. The image was split into red, 
green and blue channels. Free hand technique was used to identify the area of 
lesion in the red and green channels, followed by marking a similar sized area of 
the background from the macroscopically normal area on white light imaging in 
the red and green channels. The autofluorescence ratio and index were then 
calculated. First of all the red to green ratio of the lesion was measured by 
dividing the mean colour tone of the lesion in the red channel to that of the mean 
green channel (AF ratio). Similarly, the red to green ratio of the normal 
background was measured in the red and green images. The AF ratio of the lesion 
to the background value was taken as the Autofluorescence index or colour 
contrast index (CCI) 
8.2.5 Staining mice colons for elastin and collagen 
The mice colons were stored in formalin after AF imaging and were subsequently 
embedded into paraffin and cut into sections including the lesions and the 
background of the imaged colon. These sections were stained with Verhoeffs Van 
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Gieson (EVG) stain. The principle of this staining technique is not wen known. It 
is hypothesised that hydrogen bond is fonned between certain parts of elastic fibre 
and phenolic group of resorcin in the EVG stain. Elastin is stained blue-black and 
the collagen fibres appear as red (Figuresl-4). The rest of the tissue including 
muscle fibres would appear yellow. 
8.2.6 Quantifying the amount of collagen and elastin with ImageJ 
The amount of collagen and elastin was quantified using ImageJ software. A plug-
in known as 'threshold colour' plug-in was installed into the software for analysis. 
The EVG stained colonic images were magnified up to 20 times and were opened 
by ImageJ. All images were standardised with regards to the resolution and size. 
The original images were 24 bit in RGB fonnat. For the purpose of analysis, they 
were changed to 8 bit on the ImageJ software. The images were then analysed 
using the 'threshold' where the area of interest would appear in red. Prior to 
measurement it was con finned that the 'red' area includes both the elastin and 
collagen as depicted in the original images (stained in red and blue-black) (Figure 
5,6). Analysis was done by 'analyse particles' prompt on the software which 
provides the measure of the percentage of the total image area covered by the 
measured object and is tenned as area fraction. The area fraction in our analysis is 
a measure of the area of tissue covering collagen and elastin and represents what 
fraction of the tissue it comprises. 
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Figure 1: Image of mice colonic lesions stained with EVG, showing collagen 
stained in red (black arrow) and elastin in blue-black (green arrow) 
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Figure 2: Image of mice colonic lesions stained with EVG, showing collagen 
stained in red (black arrow) and elastin in blue-black (green arrow) 
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Figure 3: Background colonic mucosa stained with EVG stain with collagen 
in red and elastin in blue-black 
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Figure 4: Background colonic mucosa stained with EVG stain with collagen 
stained in red and elastin in blue-black 
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Figure 5: ImageJ software with RGB image converted to a 8-bit image before 
measuring the area fraction of collagen and elastin (screen shot) 
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Figure 6: The 8 bit image is analysed with 'threshold colour' marking the 
areas of interest in red and analysing the area fraction (screen shot) 
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8.2.7 Statistical analysis 
The descriptive statistics are expressed as mean and standard deviation. The 
comparison of means was done using non parametric tests of significance (Man-
Whitney U test) taking into account the relatively small number of cases. P<0.05 
was considered statistically significant 
8.3 Results 
A total of 30 formalinised mice colons from APCmin mice were included in the 
study. These colonic specimens were that of mice sacrificed at various ages, 10 
each sacrificed at 12 weeks, 18 weeks and 24 weeks. 
8.3.1 Quantifying autofluorescence in normal colon of APCm1n 
mice sacrificed at different time points 
The autofluorescence ratio as defined by the ratio of red to green colour tone of 
the normal colonic mucosa among the 12 weeks, 18 weeks and 24 weeks mice 
colons were compared (table I). The mean (± standard deviation) AF ratio of 
macroscopically normal colonic mucosa from APCmin mice sacrificed at 12 weeks 
was 0.36 ± 0.06, 18 weeks was 0.39 ± 0.05 and 24 weeks was 0.47 ± 0.07. There 
was a statistically significant increase in the AF ratio between 12 and 24 weeks 
(p=0.003) and between 18 and 24 weeks (p=0.005) but no significant difference 
between 12 and 18 weeks (p=O. I 8). 
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Table 1: Autofluorescence ratio (red/green tone) of background mice colonic 
mucosa and mice colonic lesions of different ages 
Age of mice colons AF ratio of background colonic AF ratio of Colonic lesions 
mucosa (mean ± SO) (mean± SO) 
12 weeks 0.36 ± 0.06 0.35 ± 0.05 
18 weeks 0.39 ± 0.05 0.38 ± 0.05 
24 weeks 0.47 ± 0.07 0.45 ± 0.05 
P value 12 Vs 18= 0.18 12 Vs 18= 0.27 
18 Vs 24= 0.005* 18 Vs 24= 0.015* 
12 Vs 24= 0.003* 12 Vs 24= 0.001 * 
SO-Standard deviation 
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Table 2: Area fraction of collagen and elastin in background mice colonic 
mucosa and colonic lesions of different age groups 
Age of mice colons Area fraction of Collagen and Area fraction of Collagen and 
Elastin in background colonic Elastin in colonic lesions 
mucosa (mean ± SD) (mean ± SD) 
12 weeks 1.0S ± 0.57 2.19 ± 1.1 
IS weeks 1.41 ± 0.S4 3.SS ± 2.5 
24 weeks 1.54 ± 1.0 4.69± 2.6 
P value 12 Vs IS= 0.33 12 Vs IS= 0.23 
18 Vs 24= 0.97 IS Vs 24= 0.33 
12 Vs 24= 0.41 12 Vs 24= 0.01 * 
SD-Standard deviation 
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8.3.2 Autofluorescence in mice colonic lesions from different ages 
The autofluorescence ratio of the colonic lesions among the 12 weeks, 18 weeks 
and 24 weeks mice colons were compared (table I). The mean (± Standard 
deviation) autofluorescence ratio for the APCmin mice sacrificed at 12 weeks was 
0.3S ± O.OS. The mean AF ratio was 0.38 ± 0.05 for colonic lesion in APCmin mice 
sacrificed at 18 weeks. There was no statistical significance between these results 
(P=0.27). The mean AF ratio for colonic lesions in APCmin mice sacrificed at 24 
weeks was 0.45 ± O.OS, which was significantly higher than that at 12 weeks 
(p=O.OOI) and 18 weeks (p=O.OIS). 
8.3.3 Elastin and collagen staining 
The area fraction of collagen and elastin in mice colonic lesions and nonnal 
background areas were compared in the 12, 18 and 24 week old mice colons (table 
2). The mean area fraction of elastin and collagen in macroscopically normal 
background mucosa from APCmin mice sacrificed at 12 weeks was (mean ± SO) 
1.08 ± 0.S7; 18 weeks was 1041 ± 0.84, and 24 weeks was I.S4 ± 1.0. There was 
no statistical difference between these groups (p=0.33 for 12 Vs 18 weeks, p=0.41 
for 12 Vs 24 weeks and p=0.97 for 18 Vs 24 weeks), even though there was a 
trend towards increase in the amount of elastin and collagen as the mice colonic 
age increases. 
The area fraction of elastin and collagen of colonic lesions in APCmin mice 
sacrificed at different time points was also compared. The mean area fraction for 
elastin and collagen from APCmin mice sacrificed at 12 weeks was 2.19 ± 1.1, 18 
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weeks was 3.88 ± 2.5, and for 24 weeks was 4.69 ± 2.6. There was a significant 
increase in the area fraction of collagen and elastin between 12 weeks and 24 
weeks (p=O.OI). There was no statistically significant difference between 12 and 
18 weeks (p=O.23) as well as 18 and 24 weeks (p=O.33). There was a trend 
towards an absolute increase in the amount of collagen and elastin as age of the 
colonic lesions increased 
8.4 Discussion 
This study used a well known mouse model for colon cancer (APCmin) for 
quantification of autofluorescence and to compare the ratio of AF to reflected light 
intensity with the amount of collagen and elastin in the submucosal tissue. The 
APCmin mice colons were chosen as they are well known and well characterised 
mouse model for intestinal neoplasia. The genetic and morphological changes in 
the normal as well as neoplastic mucosa have been reported before 225,227,228, 
There are no similar animal models for Barrett's early neoplasia to perform such a 
study; hence the APCmin mouse colon model was used. 
The difference in autofluorescence detected between normal and dysplastic lesions 
in the GI tract is not well established. Previous studies on colonic tissue have 
identified strong fluorescence in the submucosal layer, which could correspond to 
the amount of collagen and elastin. No difference in fluorescence was found at the 
mucosal layer between normal and abnormal tissue. Thus it was hypothesised that 
the decreased fluorescence found in dysplastic and neoplastic tissue could be due 
to the screening effect of mucosal thickening or due to replacement of submucosal 
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layer by cancer cells thus reducing the amount of collagen 220. This study was 
perfonned on human colonic tissue obtained from resection of lesions. Another 
study perfonned on whole colonic crypts and short term primary cultures of 
epithelial cells attributed the difference in autofluorescence to the intrinsic 
numbers of mitochondria and lysosomes. This study did not examine the role of 
submucosal collagen as only epithelial tissue was isolated for the study 229. 
In our study, we used formalinised mice colons for imaging followed by 
assessment of the collagen and elastin in the submucosal layer. This study has 
clearly identified an increase in autofluorescence ratio (red/green tone) and a 
reduction in autofluorescence as the age of the mice colon increases. The 
background mucosa of these genetically modified mice showed a reduction of 
fluorescence between 12 and 24 weeks and 18 and 24 weeks which clearly implies 
that as the colon becomes genetically abnormal and with increasing age the 
autofluorescence decreases. This was true in case of colonic lesions in the mouse 
model as well and as age advanced the lesions became less fluorescent which was 
statistically significant between 12 weeks and 24 weeks as well as 18 weeks and 
24 weeks. These findings show that the fluorescence decreases as the dysplasia 
progresses over the period of time and provides a biological basis for the 
quantification of autofluorescence from video autofluorescence endoscopy. 
Following the AF imaging, the APCmin mice colons and the lesions were cut into 
sections and stained with EVG. This demonstrated the amount of collagen in red 
colour and the elastin in blue black. These stained sections from the lesion and the 
background was examined to quantify the amount of connective tissue. The 
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principal finding was that there is an absolute increase in the percentage of tissue 
area with collagen and elastin in colonic lesions of 12 and 24 week old APCmin 
mice. Interestingly, there was no significant difference in the amount of collagen 
and elastin in the background mucosa. These findings demonstrate the fact that the 
reduction in fluorescence and an increase in the autofluorescence ratio in colonic 
lesions is not due to a reduction in the collagen and elastin. On the contrary, the 
connective tissue area fraction is more in the colonic lesions as age advances. The 
difference in autofluorescence between macroscopically normal tissue and tumour 
is thought to be due to various reasons. This is believed to be either due to changes 
in the physical structure such as thickening of the epithelium or due to tumour 
tissue, secondary to changes in the blood volume or due to the changes in the 
content of various fluorescent substances in the tissue like flavins and NADH in 
the mucosa or collagen in the sub mucosa 230-232, However the study by Izuishi et 
al found that, in colonic specimens there was no difference between the amount of 
flavins in the normal and diseased tissue. There was strong fluorescence detected 
in the colonic sub mucosal layer using fluorescence microscopy and this was from 
the collagen content of the tissue. The reduction in fluorescence in neoplastic 
tissue was thought to be due to either a reduction in collagen due to tumour 
infiltration or due to changes in the physical structure such as thickening of the 
mucosal layer due to the neoplastic process 220. In our study we have demonstrated 
that the actual amount of collagen and elastin increases with increasing age of the 
colonic lesions with a reduction in fluorescence. The most likely explanation for 
the reduction in autofluorescence in the colonic lesions would be due to the 
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mucosal thickening associated with the lesion which attenuates the 
autofluorescence as the light could not penetrate through the thickened mucosa to 
reach the collagen and elastin. 
8.4.1 Limitations of the study 
This study was performed on formalinised mice colons from 12, 18 and 24 weeks 
old APCmin mice. The autofluorescence of tissue depends on various factors 
including presence of blood flow and mucosal flavins and NADH. This study was 
intended to assess autofluorescence and its correlation with submucosal collagen 
and elastin. Because we used formalinised tissue we could not assess the effect of 
blood flow, haemoglobin content or assess the amount of other auto fluorescent 
substances in the tissue. 
8.4.2 Conclusions 
The ratio of fluorescent to reflected light reduces with increasing age of the 
APCmin mice in both the macroscopically normal colonic mucosa and colonic 
lesions which supports the hypothesis that AF reduces with worsening dysplasia. 
The amount of sub mucosal collagen, which is known to be the strongest tissue 
fluorophores, increases in the colonic lesions of APCmin mouse as age advances. 
The reduction in AF is unlikely to be due to reduction in collagen but could very 
well be due to physical changes to the mucosal structure such as increased 
thickening due to the neoplastic process. Further studies are needed of AF imaging 
of pre-operative adenocarcinoma/dysplasia patients with Barrett's oesophagus and 
correlate this with the submucosal collagen in the resected specimens. 
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9.1 The role of multimodal imaging in Barrett's oesophagus 
The challenge during Barrett's surveillance is to identify subtle and inconspicuous 
lesions at an early stage. This is often difficult as some of the dysplastic lesions 
are flat. An early intervention either endoscopically or surgically would prevent 
development of symptomatic cancers. There are various simple techniques which 
an endoscopist could adopt to improve visualisation such as cleaning thoroughly 
and using mucolytics to visualise the Barrett's segment well. However, it is argued 
that image enhanced endoscopy and high definition endoscopy could improve the 
yield of dysplasia during Barrett's surveillance. 
This thesis examined the value of different modalities of imaging in Barrett's 
oesophagus. The endoscopy systems in the modem world have significantly 
improved in resolution and picture quality. By altering the light wavelengths and 
introducing filters, we are able to offer narrow band imaging and autofluorescence 
imaging to utilise the tissue characteristics and thus identify subtle changes in 
mucosal architecture. 
The resolution of endoscopes has improved significantly over the past decade. The 
first study utilised a regular Barrett's surveillance population to investigate 
whether there is a difference in identifying dysplasia between high definition and 
standard definition endoscopy. This is a retrospective analysis of clinical data 
obtained from Nottingham University Hospitals NHS Trust. There was no 
significant difference between the HD and SD group in terms the age and gender 
of the patients. The HD endoscopy was found to be superior to SD endoscopy in 
targeted detection of an dysplasia and detection of dysplasia with random and 
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targeted biopsies combined. We have included indefinite for dysplasia in this 
group which could be the reason for the significant differences seen. However, 
there was no difference between HO and SO in detecting HGO/cancer. This could 
be due to the fact that the absolute number of cases with HGO/cancer was small in 
both groups. It is difficult to conclude whether HO endoscopy is superior to SO in 
Barrett's surveillance based on this small retrospective study; however HO system 
could be used wherever available as a preferred option for BO surveillance. 
Narrow band imaging is a technique used to highlight the mucosal vascular 
patterns by increasing the contribution of blue light. The pit patterns are also 
distinctly seen and there are various studies which investigated the accuracy of 
various pit patterns and vascular patterns in predicting dysplasia in Barrett's 
oesophagus. NBI with magnification (NBI-Z) of the suspicious areas could 
provide significant details of the mucosal surface patterns. A meta-analysis 
showed that the accuracy of this technique is more than 95% when analysed both 
on a per-patient and per-lesion analysis for characterising HGO/cancer. The 
studies included are all from centres of excellence and performed on an enriched 
Barrett's population. However, NBI-Z could be a valuable tool to characterise a 
lesion prior to target biopsying and also to examine suspicious and subtle lesions. 
This study does not address whether detection of dysplasia is superior with NBI as 
there is a paucity of literature on this aspect. 
Autofluorescence endoscopy is a relatively new technique which is proposed to be 
useful as a red flag technique to detect areas of dysplasia and these lesions could 
be closely observed with magnification endoscopy or NBI for further 
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characterisation. This would be an ideal technique for wide field imaging 
especially in long segment Barrett's to focus areas of abnormality. A meta-
analysis was performed to identify the incremental yield of AFI over white light 
endoscopy in detecting dysplastic lesions. AFI showed a 49% increased yield of 
HGD/cancer and 46% incremental yield for detecting all dysplasia over WLE. 
This is at the expense of detecting significant number of false positive areas. 
Nonetheless, AFI is a valuable tool to improve the yield of dysplasia, particularly 
if it is possible to define what constitutes a true positive AFI signal. 
A true positive AF signal was proposed to be magenta in colour with opaque 
intensity, away from gastric folds and that shows mucosal irregularities in white 
light endoscopy. These criteria were included in an inter-observer study including 
74 sets of white light and AFI images of corresponding areas of Barrett's 
oesophagus. A training presentation was offered to both AFI experts an non-
experts followed by scoring the images. Among experts, the inter-observer 
agreement was only fair to moderate when AF images were shown which 
improved when white light images were also displayed. The overall accuracy in 
identifying dysplasia was modest. This study clearly shows the need for 
improvement in this technique which could be achieved by improving technical 
aspects or by creating an objective measure of the autofluorescence intensity. 
An objective way to assess the AF intensity of an area of interest is by measuring 
the ratio of the red to green colour tone (AF ratio) and when the AF ratio of the 
lesion to that of background is calculated, this is called AF index. A pilot study 
was performed using 82 AF images from patients with Barrett's oesophagus 
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which was correlated with histology. A cut off value of 1.32 for the AF index was 
selected arbitrarily, based on the receiver operating curve of several AF indices. 
This was validated using the same dataset which is the limitation of this study, but 
this has raised the potential of an objective index which could very well be 
incorporated to real time endoscopy. Real time prospective studies are necessary 
to assess the value of such an index. 
The biological basis of the phenomenon of autofluorescence is debatable. Various 
fluorophores in the gastro-intestinal tract were implied. The strongest fluorophores 
are thought to be submucosal collagen and elastin. It is well known that the 
autofluorescence reduces when tissue becomes dysplastic. It is not clear whether 
this reduction in fluorescence is due to a reduction of collagen and elastin in the 
submucosal tissue or due to the mucosal thickness reducing the fluorescence. A 
genetically modified mouse colonic model was used as Barrett's animal models 
are not available. The colonic lesions were imaged with autofluorescence 
endoscopy and the AF ratio was calculated as described earlier. This was followed 
by staining for collagen and elastin. This study showed that the ratio of fluorescent 
to reflected light reduces with increasing age of the APCmin mice, both in the 
macroscopically normal colonic mucosa and in colonic lesions. This supports the 
hypothesis that AF reduces with worsening dysplasia. The amount of sub mucosal 
collagen, which is known to be one of the strongest tissue fluorophores, increases 
in the colonic lesions of APCmin mouse as age advances. The reduction in AF is 
unlikely to be due to reduction in collagen but could very well be due to physical 
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changes to the mucosal structure such as increased thickening due to the 
neoplastic process. 
In conclusion, high definition and autofluorescence imaging improve targeted 
detection of dysplasia in Barrett's oesophagus. NBI with magnification has a high 
accuracy in characterising HGD/cancer in Barrett's oesophagus. However, none of 
these techniques could replace random biopsies. There is limited agreement 
regarding what constitutes a true positive autofluorescence signal. Methods to 
quantify autofluorescence intensity are likely to reduce the false positive rates of 
AFI. The intensity of AFI reduces with worsening dysplasia and is likely to be due 
to thickening of the mucosal layer. 
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